Category: 3. Business

Knee-jerk corporate responses to data leaks protect brands like Qantas — but consumers are getting screwed | Cybercrime

It’s become the playbook for big Australian companies that have customer data stolen in a cyber-attack: call in the lawyers and get a court to block anyone from accessing it.

Qantas ran it recently after suffering a major cybersecurity attack that accessed the frequent flyer details of 5 million customers.

The airline joined the long list of companies in Australia, dating back to the HWL Ebsworth breach in 2023, to go to the NSW supreme court to obtain an injunction against “persons unknown” – banning the hackers (and anyone else) from accessing or using the data under threat of prosecution.

Of course, it didn’t stop hackers leaking the customer data on the dark web a few months later.

But it might have come as a surprise when ID protection company Equifax this month began alerting Qantas customers that their data had been leaked – since access to the data was supposedly banned.

This highlights the major flaw in the injunction scheme. Qantas argues the injunction protects customers, but cybersecurity experts warn that in practice it has the opposite effect: scammers will ignore it, while organisations based in Australia and operating within the law will not be able to verify the data and report on it.

_{Sign up: AU Breaking News email}

Troy Hunt, an Australian who operates the HaveIBeenPwned website which notifies users when their information appeared in breaches, is frustrated that he has not been able to include the breach in his searchable database.

“Clearly the injunction has not stopped even legally operating organisations from accessing the data and communicating with the customers,” he said.

“[Qantas is] obviously trying to minimise damage, and they will inevitably get raked over the coals with class actions, because it happens to every big company that has a breach now … but there is just no measurable, practical benefit that anyone can assign to keeping this data out of the hands of people like [me], whilst it’s in the hands of people who are now abusing it.”

Hunt noted the irony that Qantas’s cybersecurity incident statement on its website links out to government resources for customers caught up in a breach. Those resources advise customers to visit Hunt’s website so they can better protect themselves by being aware of what information is out there.

How Equifax approached the injunction is unclear. The company said it uses the cybersecurity company Norton to monitor the dark web. Norton’s parent company Gen Digital is based in the US and Czechia while Equifax is US-based.

Norton did not deny it had accessed the data when asked twice by Guardian Australia, saying in a statement it is “contractually obligated to notify customers” when their information is posted on the dark web.

“These alerts are part of our ongoing commitment to help victims of a data breach protect their personal information and respond quickly if their data is at risk,” the spokesperson said. “This service operates under strict business, privacy, and compliance standards to ensure accuracy and lawful handling of all data sources.”

Qantas would not confirm if it was considering pursuing companies for potential contraventions of the injunction, but indicated it was monitoring third-parties and would consider them on a case-by-case basis.

“We are aware of notifications being sent to some of our customers by a third-party providers. These notifications include types of personal information that was not held in the system impacted in our July cyber incident,” the spokesperson said.

According to screenshots from the Telegram group run by the hackers, posted this month by Hunt, the hackers are aware of the limitations of the injunction.

“qantas why are you lying to your citizens?” the message states. “all your injunction does is prevent media/journalists.”

“YOUR data WILL be released and it WILL BE accessed.”

Continue Reading

November 1, 2025
Geoffrey Hinton says tech giants can’t profit from AI investments unless human labor is replaced

Computer scientist and Nobel laureate Geoffrey Hinton doubled down on his warnings about how artificial intelligence will affect the labor market and the role of companies leading the charge.

In an interview with Bloomberg TV’s Wall Street Week on Friday, he said the obvious way to make money off AI investments, aside from charging fees to use chatbots, is to replace workers with something cheaper.

Hinton, whose work has earned him a Nobel Prize and the moniker “godfather of AI,” added that while some economists point out previous disruptive technologies created as well as destroyed jobs, it’s not clear to him that AI will do the same.

“I think the big companies are betting on it causing massive job replacement by AI, because that’s where the big money is going to be,” he warned.

Just four so-called AI hyperscalers—Microsoft, Meta, Alphabet and Amazon—are expected to boost capital expenditures to $420 billion next fiscal year from $360 billion this year, according to Bloomberg.

Meanwhile, OpenAI alone has announced a total of $1 trillion in infrastructure deals in recent weeks with AI-ecosystem companies like Nvidia, Broadcom and Oracle.

When asked if such investments can pay off without destroying jobs, Hinton replied, “I believe that it can’t. I believe that to make money you’re going to have to replace human labor.”

The remarks echo what he said in September, when he told the Financial Times that AI will “create massive unemployment and a huge rise in profits,” attributing it to the capitalist system.

In fact, evidence is mounting that AI is shrinking opportunities, especially at the entry level, and an analysis of job openings since OpenAI launched ChatGPT shows they plummeted roughly 30%.

And this past week, Amazon announced 14,000 layoffs, largely in middle management. While CEO Andy Jassy said the decision was due to “culture” and not AI, a memo he sent in June predicted a smaller corporate workforce “as we get efficiency gains from using AI extensively across the company.”

Despite the potential downside for workers, Hinton also sees benefits from AI. When asked if he would go back in time and stop AI from developing, he paused and said he doesn’t know.

“It’s not like nuclear weapons, which are only good for bad things,” he explained. “It’s a difficult decision because it can do tremendous good in healthcare and education. It’ll do tremendous good, and in fact if you think about it increasing productivity in many, many industries, that should be good.”

The problem ultimately is not due to AI itself, but “on how we organize society,” Hinton added.

Continue Reading

November 1, 2025
Adaptive ER stress promotes mitochondrial remodelling and longevity through PERK-dependent MERCS assembly

PERK promotes myogenesis in myoblasts subjected to physiological levels of ER stressors

To investigate the role of adaptive UPR^ER during myogenesis, C2C12 myoblasts were exposed to a range of concentrations of the ER stressor tunicamycin (TM) for 8 h, followed by differentiation into myotubes (Supplementary Fig. 1A). Notably, treatment of myoblasts with 0.2 μg/ml TM significantly enhanced the myogenic potential of myoblasts. However, concentrations above 0.4 μg/ml were detrimental and promoted cell death (Supplementary Fig. 2A). To determine if the response was an ER stress response or specific to TM, the SERCA inhibitor thapsigargin (TG) was also used. A low concentration of TG (10 nM) also promoted an increase in myogenic parameters (Supplementary Fig. 2B). Inhibition of PERK with AMG PERK44 (AMG) resulted in no difference in myogenesis parameters compared to controls (Fig. 1A). Furthermore, the combined AMG + TM treatment group (AMG + TM) exhibited no change when compared to the AMG group (Fig. 1A). However, inhibition of IRE1α with MKC8866 (MKC) led to a significant decrease in all the parameters compared to controls (Fig. 1A). Nevertheless, the MKC + TM group exhibited an increase in myogenic parameters compared to MKC alone (Fig. 1A). Interestingly, TM-treated myoblasts exhibited a significant decrease in cell viability, with an even greater decrease observed in the AMG + TM group (Supplementary Fig. 2C).

Fig. 1: Treatment of C2C12 myoblasts with an acute low concentration of the ER stressor tunicamycin (TM) promotes myogenesis.

A MF20 immunostaining following TM 0.2 μg/mL treatment of myoblasts resulted in an increase in myotube diameter, area and fusion index. Mean ± SEM; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001 One-way ANOVA. B PCR analysis of mRNA expression levels of XBP1s/XBP1u in TM-treated myoblasts. Each lane represents independent biological replicates, data represented as mean ± SEM; ****p ≤ 0.0001 Student’s t test. C–E Western blot of ATF4, CHOP and p-EIF2α/EIF2α in TM-treated myoblasts. Each lane represents independent biological replicates, data represented as mean ± SEM; *p ≤ 0.05 and **p ≤ 0.01 One-way ANOVA. F MF20 immunostaining following TM treatment 0.2 μg/mL of myotubes, n = 5. Scale 275 μm. Mean ± SEM; Student’s t test.

PCR analysis confirmed activation of the IRE1α arm of the UPR^ER, with a shift toward the spliced, active form of XBP1 (XBP1s) following TM treatment (Fig. 1B). Western blot analysis of UPR^ER markers revealed no significant changes in the ER chaperone GRP78, though there was an increasing trend in eIF2α phosphorylation (Supplementary Fig. 2D). There was an increase in the levels of ATF4 in MKC + TM-treated cells, and increasing trend in eIF2α phosphorylation, while CHOP increased following TM treatment and was elevated in both AMG + TM and MKC + TM groups (Fig. 1C–E). To evaluate the different UPR pathways, we performed a qPCR analysis of markers of the mammalian UPR^ER (Hspa5, Dnajc3, Ddit3, Herpud1, Pdia4 and Edem1) [44] and UPR^mt (Atf5, Lonp1, Hspe1, Hspa1a, Hspd1 and Hsp90aa1) [45]. A similar response in all UPR^ER markers was observed, a slight increase in gene expression with the TM treatment, however there was a significant increase in levels of UPR^ER genes following TM treatment in combination with the PERK inhibitor (Supplementary Fig. 2E). The expression of UPR^mt genes Atf5 and Lonp1, follow the same pattern as the UPR^ER markers, however, the gene expression of Hspe1, Hspa1a, Hspd1 and Hsp90aa1 did not change (Supplementary Fig. 2F). Similar to inhibition of PERK with AMG44, knock-down of PERK (siPERK) in myoblasts decreased myotube diameter following differentiation. Knock-down of PERK or CHOP combined with the TM treatment, exhibited a reduction in myotube area and fusion index compared to siRNA CNT (Supplementary Fig. 2E). Additionally, TM treatment of differentiated, untreated myotubes did not result in any significant differences in the myotube parameters (Fig. 1F). Collectively, these findings demonstrate that inducing mild ER stress in myoblasts improved myogenesis and identified an essential role of PERK in adaptive UPR signalling.

PERK promotes MERCS assembly and mitochondrial adaptations during adaptive UPR

The effects of TM treatment (0.2 μg/ml for 8 h) and/or PERK inhibition on mitochondrial content and function were evaluated in myoblasts (Fig. 1A). MitoTracker Green staining was used to assess mitochondrial content and increased with TM treatment. No differences were observed between the AMG group and the controls (Fig. 2A). Mitochondrial ROS was assessed using MitoSOX staining and there was no change in MitoSOX staining in the TM and AMG groups. However, an increase in fluorescence was observed in the AMG + TM group (Fig. 2A). Additionally, MitoTracker Green and TMRE staining was used to assess mitochondrial membrane potential (ΔΨm), there was a significant increase in both MitoTracker Green and TMRE staining following TM treatment. The ratio of the intensities indicated that TM treatment promoted mitochondrial biogenesis and enhanced ΔΨm (Supplementary Fig. 2F). Both the mitochondrial fusion protein MFN2, which plays a role in mitochondrial-ER tethering [46, 47], and the mitochondrial content indicator TOM20 increased with TM treatment (Fig. 2B, C). The oxygen consumption rate of C2C12 myoblasts demonstrated enhanced basal and maximal respiration, non-mitochondrial respiration, and ATP production in TM-treated cells compared to controls, AMG, and AMG + TM groups (Fig. 2D, E). Furthermore, transmission electron microscopy (TEM) organelle ultrastructure analysis of myoblasts demonstrated an increase in the membrane surface area of mitochondria (S_A), mitochondrial elongation (aspect ratio) following TM treatment; these adaptations were blocked by PERK inhibition (Fig. 2F, G). Notably, these mitochondrial adaptations were preserved following differentiation into myotubes (Fig. 2I, J). Additional parameters, including mitochondrial volume fraction, cristae membrane density (S_A IMM/OMM) and ER surface area, increased in both myoblasts and subsequent myotubes following TM treatment (Supplementary Fig. 2G). The evaluation of MERCS surface area demonstrated an expansion of mitochondrial and ER membranes that are in close proximity following TM treatment. The formation of these expanded subdomains was blocked by inhibition of PERK (Fig. 2F–H). The increase in MERCS surface area was sustained after differentiation into myotubes (Fig. 2I–K). Together, the data demonstrates that PERK is required during adaptive UPR^ER to form MERCS and increase mitochondrial content and function in myoblasts, which were maintained following differentiation into myotubes.

Fig. 2: Adaptive UPR^ER signalling increases mitochondrial capacity and MERCS assembly that depends on the PERK arm of the UPR^ER.

A TM treatment increased mitochondrial content (MitoTracker Green) but did not affect MitoSOX staining; n = 3. Scale 40 μm. Mean ± SEM; * p ≤ 0.05 and **p ≤ 0.01 One-way ANOVA. B, C Increased levels of MFN2 and TOM20 in TM-treated myoblasts. Each lane represents independent biological replicates, data represented as mean ± SEM; *p ≤ 0.05 and **p ≤ 0.01 One-way ANOVA. D, E TM treatment of myoblasts increased basal and maximal respiration rate, ATP production and non-mitochondrial respiration. Mean ± SEM; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001 One-way ANOVA. F, G, H Representative TEM images of sections of myoblasts. Mitochondrial surface area, aspect ratio and MERCS surface area increased with the TM treatment. PERK inhibition resulted in no differences compared to the control.; n = 4. Scale 200 nm. Mean ± SEM; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001 One-way ANOVA. I, J, K Representative TEM images of sections from myotubes following TM treatment of myoblasts demonstrating the increase in mitochondrial surface area, aspect ratio and MERCS surface area was maintained in myotubes following TM treatment.; n = 4. Scale 200 nm. Mean ± SEM; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001 One-way ANOVA.

PERK is required for adaptive UPR^ER activation of autophagy and mitophagy

To determine the mechanisms underlying the adaptations promoted by the UPR^ER in myoblasts, proteomic changes induced by an 8 h treatment with 0.2 μg/ml TM was performed. Global label-free proteomics quantified 2513 proteins, 71 proteins were significantly upregulated and 27 downregulated following TM treatment (Fig. 3A). Enrichment analysis of the 71 significantly upregulated proteins identified several pathways and proteins involved in Mitophagy and mitochondrial ADP/ATP transport (ADRO, TPP1, TXTP, MTDC, SYHM, RM12, KAPCA, ADT1 and ADT2), indicating active remodelling of the mitochondrial network and mitochondrial respiration (Supplementary Fig. 2J, K). Also, upregulated were proteins related to Cell cycle and differentiation (PTBP3, RCC1, CCNK, MD1L1 and MYH10) (Fig. 3A, B). One of the most significantly upregulated proteins was ERD22, a member of the KDELR family highly involved in the maintenance of ER homeostasis during adaptive UPR^ER signalling [48]. There was a significant increase in gene expression of Kdelr2 following TM treatment (Supplementary Fig. 2L). No significant pathway enrichment was identified among the 27 downregulated proteins, which spanned diverse biological processes, including mitochondrial RNA processing and protein translation (4EBP1, MRT4, RPR1B and EI2BA) (Fig. 3A).

Fig. 3: Adaptive UPR^ER signalling in myoblasts promotes autophagy and mitochondrial turnover.

A Volcano plot of LFQ proteomic data of protein abundance following TM treatment (FDR = 1.58%). The cut-offs (represented as dotted lines) for significant changes are FC > 1.5 and P < 0.01. Blue dots indicate down-regulated proteins, red dots indicate up-regulated proteins. Four biological replicates per condition. B GOBP ShinyGO enrichment of significantly upregulated proteins. C Graphical diagram of the pH-sensitive construct for visualisation of mitochondrial turnover. D, E Increased mitophagy in TM treated myoblasts, represented by a decrease in the GFP/RFP ratio.; n = 3. Mean ± SEM; **p ≤ 0.01 Student’s t test. Scale 25 μm. F, G Western blot of protein extracts for p62 and LC3 II/I. Each lane represents independent biological replicates, data represented as mean ± SEM; *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 One-way ANOVA. H Representative TEM images of sections of TM treated myoblasts and quantification of the lysosome, autophagasomes and autolysosome fractions. n = 4. Scale 400 nm. Mean ± SEM; *p ≤ 0.05 and **p ≤ 0.01 One-way ANOVA. I Representative TEM images of sections of myotubes treated with TM at myoblast stage and quantification of lysosome, autophagasome and autolysosome fractions. n = 4. Scale 400 nm. Mean ± SEM; *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 One-way ANOVA.

To further explore mitochondrial turnover, live-cell imaging was performed using the mitophagy reporter plasmid [Cox8-EGFP-mCherry] [49], transfected into myoblasts before TM treatment. The reporter contains a pH-sensitive GFP and a pH-stable RFP to track mitochondrial turnover; GFP fluorescence is quenched in acidic lysosomes, while RFP remains stable, allowing an estimation of mitophagy (Fig. 3C). TM treatment significantly reduced the GFP/RFP ratio compared to the control group, indicating an induction of mitophagy (Fig. 3D, E). Western blot analysis of autophagy-related proteins revealed that ULK1 levels were elevated in the TM group compared to the CNT, AMG, and AMG + TM groups (Supplementary Fig. 2M). p62 levels increased in the AMG and AMG + TM groups compared to the CNT and TM groups, indicating reduced autophagic flux (Fig. 3F). Finally, increased expression of ATG5 (Supplementary Fig. 2N) and LC3-II/I (Fig. 3G) in the TM group indicates enhanced autophagosome formation. Ultrastructure analysis of the autophagic bodies by TEM, evaluated changes in the volume fraction of lysosomes, autophagosomes and autolysosomes from myoblasts and myotubes. Myoblasts exhibited an apparent increase in the volume fraction of lysosomes and autolysosomes in the TM group compared to CNT, AMG and AMG + TM groups (Fig. 3H). In contrast, myotube analysis indicated no change in lysosome or autolysosomes volume fractions between groups, although there was a decrease in autophagosome volume in the TM group compared to the CNT and AMG + TM groups (Fig. 3I). Changes in [Ca²⁺]_i showed a slight, but not significant, increase in the maximal increase of store-operated calcium entry (SOCE) from the TM-treated myoblasts compared to controls (Supplementary Fig. 2O). Additionally, ER volume was assessed using an ER-targeting plasmid [ER (KDEL)-mNeonGreen] to estimate the ER membrane area relative to cellular surface area, revealing a significant expansion in ER membrane area following TM treatment (Supplementary Fig. 2P). Overall, proteomic and ultrastructural analyses revealed that TM treatment induces mitophagy and enhances autophagic flux during myogenesis. These adaptations depend on PERK activity and potentially play a crucial role in regulating organelle turnover.

Early-life induction of the UPR^ER extends lifespan and preserves healthspan in C. elegans

C. elegans was used as a physiological model to assess the role of UPR^ER signalling in a whole organism. To replicate the in vitro myogenesis model, worms were treated at an early developmental stage. Following bleaching, embryos were harvested and exposed to 1.25 μg/ml TM in S Medium for 24 h and larvae plated and allowed to develop normally (Supplementary Fig. 1B) [50]. There was an increase in the longevity of TM-treated worms compared to controls (Fig. 4A). To determine if the response was an ER stress response or specific to TM, the SERCA inhibitor TG was used. Treatment with 150 nM of TG also promoted an increase in lifespan and increased filamentous mitochondrial network (Supplementary Fig. 3A, B). Reproductive potential was significantly reduced in the TM group (Fig. 4B). Importantly, this decrease in progeny was not associated with increased embryo lethality (Supplementary Fig. 3C). Interestingly, TM-treated worms exhibited increased body length compared to controls (Fig. 4C). The activation of both the UPR^ER and the UPR^mt was confirmed using transcriptional GFP reporter strains for hsp-4 (orthologue of mammalian HSPA5/Grp78) and hsp-6p (ortholog of the human mtHSP70). TM treatment resulted in greater UPR^ER and UPR^mt activation capacity compared to controls (Fig. 4D, E). Analysis of the IRE-1 branch of the UPR revealed increased splicing of XBP-1 in TM-treated worms (Fig. 4F). The survival of the worms against a range of different toxicants was assessed. The resistance of the TM treated group against sodium arsenite, the redox cycler Paraquat and the organic peroxide tBuOOH was higher than the control group at adult day 1 (Fig. 4G–I). CeleST (C. elegans Swim Test) was performed to assess physical fitness and mobility during ageing [42]. The fitness levels were evaluated on days 1, 5, 10 and 15 of adulthood. Fitness markers including wave initiation rate, travel speed and activity index decreased with age in both groups but remained significantly higher in TM-treated worms compared to controls at all time points (Fig. 4J, Supplementary Fig. 3D, E). Conversely, frailty markers including stretch, average body curvature and curling increased with age in both groups, but these were consistently lower in the TM group, indicating better maintenance of physical health in the TM-treated groups (Fig. 4K, Supplementary Fig. 3F, G). The results demonstrate that early-life UPR^ER activation extends lifespan, increases stress resistance and promotes healthspan by preserving physiological fitness and reducing frailty during ageing.

Fig. 4: Activation of UPR^ER in C. elegans at an early developmental stage increased longevity, stress resistance and fitness.

A Lifespan assay of TM treated N2 strain. Kaplan–Meier survival plots of two independent experiments initiated with 100 animals/group. Mean ± SEM; ****p ≤ 0.0001 Log-rank (Mantel-Cox) test. B TM treatment decreased progeny in N2 wild-type C. elegans. Data from 20 animals/group. Mean ± SEM; * p ≤ 0.05 and **p ≤ 0.01 Student’s t test. C Body length of N2 wild-type TM-treated worms. Data from 20 animals/assay. Mean ± SEM; **p ≤ 0.01 Student’s t test. D, E Activation of UPR assessed by hsp-4::GFP (UPR^ER)and hsp-6p::GFP (UPR^mt) following TM treatment. Scale 275 μm. Mean ± SEM of at least 20 animals/assay. ****p ≤ 0.0001 Student’s t test. F Semiquantitative PCR analysis of expression ratio between XBP1s:XBP1u transcripts. n = 3, Each lane represents independent biological replicates, data represented as mean SEM; **p ≤ 0.01 Student’s t test. G, H, I Survival of wild type in Sodium Arsenite, tBuOOH and Paraquat. Kaplan–Meier survival plots of two independent experiments initiated with 45 animals/group. Mean ± SEM; ****p ≤ 0.0001 by Log-rank (Mantel-Cox) test compared with wild-type control. J CeleST physical fitness parameters at days 1, 5, 10, and 15. Data mean of at least 30 animals/assay. K CeleST physical frailty parameters at days 1, 5, 10, and 15 individual values controls and TM-treated worms during ageing. Data mean of at least 30 animals/assay.

Early-life induction of the UPR promotes lifespan extension in C. elegans through modulation of lipid metabolism and lysosome activation

As TM treatment of myoblasts resulted in improved myogenesis, while treatment of myotubes was detrimental, we assessed whether the adaptations promoted by the UPR^ER during early nematode development were similar to TM treatment of adult worms. TM treatment (1.25 and 5 μg/ml for 24 h) was performed during L4 to adult Day1 developmental stage of C. elegans. Both TM treatments (1.25 and 5 μg/ml) at L4 stage resulted in a significant reduction in lifespan (Fig. 5A), along with decreased resistance to paraquat and sodium arsenite (Fig. 5B, C). Interestingly, no change in resistance to sodium arsenite was observed in worms treated with the lower TM dose (1.25 μg/ml) (Fig. 5B). This highlights that the beneficial effects of TM treatment occurred only at an early developmental stage and treatment of adult worms resulted in negative effects similar to the myogenesis model.

Fig. 5: UPR^ER activation in C. elegans embryos or at L4 stage has opposite effects on lipid metabolism.

A Lifespan analysis of N2 strain treated with TM at L4 stage. Kaplan–Meier survival plots of two independent experiments initiated with 100 animals. Mean ± SEM; **** p ≤ 0.0001 Log-rank (Mantel-Cox). B, C Decreased survival of N2 worms treated with TM at L4 stage in 10 mM sodium arsenite and 100 mM Paraquat. Kaplan–Meier survival plots of two independent experiments initiated with 50 animals/group. Mean ± SEM; *p ≤ 0.05, ***p ≤ 0.001 and ****p ≤ 0.0001 Log-rank (Mantel-Cox). Volcano plot of differentially expressed genes (DEGs) following TM treatment of embryos (D) or adults (E), red significantly upregulated genes and blue significantly downregulated genes. Four biological replicates per condition. F Dot plot of Shiny GO KEGG analysis of DEGs in embryo group. Upregulated pathways are in red and downregulated pathways are in blue. G Dot plot of Shiny GO KEGG analysis of DEGs in L4 group. Upregulated pathways are in red and downregulated pathways are in blue. H Oil Red O stained N2 worms following TM treatment at embryo or L4 stage. 3 independent experiments with at least 20 animals per strain; Scale 275 μm. Mean ± SEM; *p ≤ 0.05, **p ≤ 0.01 and ****p ≤ 0.0001 by ANOVA. I Intestine of wild-type worms incubated with LysoSensor Green (LSG) indicator of lysosomal pH and LysoTracker Red (LSR) indicator of lysosome content, three independent experiments with 10 animals per condition; Scale 50 μm. Mean ± SEM; ***p ≤ 0.001 and ****p ≤ 0.0001 by ANOVA.

RNA sequencing was performed to determine the molecular mechanisms underlying the different responses dependent on the developmental stage. A transcriptome analysis was conducted on Day 1 adults that were treated with TM 1.25 μg/ml at embryonic stage (EMBRYO group) (Fig. 5D) or treatment with TM at L4 stage (L4 group) (Fig. 5E). Differentially expressed genes (DEGs) were analysed (Log₂-fold change >1 and adjusted p-value < 0.05) from EMBRYO (FDR = 2.38%) and L4 separately (FDR = 1.1%). DEGs from EMBRYO-treated groups reported 1249 upregulated and 2042 downregulated genes. Functional enrichment analysis of the upregulated genes identified pathways related to lipid metabolism and lysosome activation (Fig. 5F). Both pathways have previously been described as key intermediates in the UPR regulation of ageing [51]. Gene set enrichment analysis (GSEA) indicated enhanced expression of genes associated with autophagy (lysosomal pathways) and mitochondrial activity (oxidative phosphorylation) (Supplementary Fig. 3I). Lipid biosynthesis emerged as the most prominent upregulated pathway and there was an increase in most intermediates of this pathway (Supplementary Fig. 4A). Gene set enrichment analysis (GSEA) indicated positive enrichment of genes associated with autophagy (lysosomal pathways) and mitochondrial activity (oxidative phosphorylation) (Supplementary Fig. 4B). In contrast, the L4 group resulted in 146 upregulated and 811 downregulated genes (Fig. 5F). Functional enrichment of the downregulated genes highlighted pathways involved in lipid metabolism and C. elegans longevity (Fig. 5G). Pathway enrichment analysis identified a reduction in the expression of intermediates in the lipid biosynthesis pathway in the L4 treated group (Supplementary Fig. 4D). GSEA revealed decreased expression of genes related to autophagy (lysosomes) and mitophagy in L4-treated worms (Supplementary Fig. 4E). These results were validated by qPCR of genes involved in lysosomal function (vha-6, asah-1 and cpr-1) and lipid metabolism (acox-1.5, elo-2 and fat-5), increased expression in the EMBRYO treated group and decreased expression of fat-5 and vha-6 in the L4 treated groups (Supplementary Fig. 4G, H). Finally, comparing the functional enrichment of downregulated genes in the EMBRYO group with the upregulated genes in the L4 group demonstrated shared pathways related to metabolism (Supplementary Fig. 3C–F). These findings suggest that UPR^ER activation during early development promotes beneficial adaptations that contribute to lifespan extension, whereas induction later in life leads to a decline in similar protective mechanisms, particularly affecting lipid metabolism and autophagy.

RNA sequencing highlighted the effects of TM treatment on lipid metabolism and the lysosome. Oil Red O staining, which stains neutral triglycerides and lipids, was performed in the different groups [40]. Interestingly, TM treatment decreased lipid staining in the EMBRYO group compared to the controls (Fig. 5J). However, in the L4 group, TM treatment increased lipid staining compared to the control group (Fig. 5J), supporting the transcriptomic data of increased expression of lipid-related genes in embryo-treated worms but a decrease in L4 treated worms. The lysosomal content and acidity were estimated using the LysoSensor green/LysoTracker red (LSG/LSR) ratio in the intestine [52]. Results demonstrated decreased pH in the lysosomes of N2 worms subjected to the TM treatment at the embryonic stage. No changes in lysosomal pH were reported in the animals treated at the L4 stage (Fig. 5K). An upregulation of lysosomal genes and increased intestinal lysosomal acidity in response to UPR^ER activation has previously been demonstrated to improve proteostasis and longevity in C. elegans [53]. RNAi knockdown of lmp-1 (ortholog of LAMP1, a lysosomal membrane protein important for lysosomal function) had no effect on longevity or in combination with TM treatment (Supplementary Fig. 3L). RNAi knockdown of lmp-1 also resulted in a more fragmented mitochondrial network after TM treatment (Supplementary Fig. 3M). These results suggest activation of autophagy is required for the adaptive UPR^ER increase in longevity and mitochondrial morphology. Overall, the effects of TM treatment were dependent on the developmental stage and resulted in the opposite expression of genes involved in lipid metabolism, and subsequent effects on longevity and oxidative stress resistance. The results support the findings in the myogenesis model and highlight increased plasticity for adaptations following UPR^ER induction at early developmental stages.

Early-life UPR induction stimulates MERCS formation, mitochondrial capacity and mitophagy in C. elegans

In order to determine if there was a similar adaptive response in nematodes to the myogenesis model following TM treatment, the effects on mitochondrial content were assessed using a transcriptional Pcox-4::GFP reporter [54]. The fluorescence intensity increased with TM treatment (Fig. 6A). MitoTracker Red staining was used to estimate mitochondrial membrane potential and there was a significant increase in the fluorescence intensity following treatment with TM (Fig. 6B), which was also observed using TMRM staining (Supplementary Fig. 3N). In addition, mitochondrial superoxide production was evaluated by MitoSOX staining, demonstrated a reduction in the TM group (Supplementary Fig. 3O). Mitochondrial respiration was assessed using adult day 1 C. elegans following treatment with TM at the embryo stage. TM-treated worms showed a slight, non-significant increase in both basal and maximal OCR, and there was a significant increase in non-mitochondrial respiration (Fig. 6C). TEM was used to analyse the mitochondrial ultrastructure of body wall muscle cells from C. elegans (Supplementary Fig. 1D). Stereological analysis revealed increased mitochondrial surface area in the TM group (Fig. 6D). Moreover, mitochondria from the TM treatment group, exhibited an increased aspect ratio, indicating more elongated, fused mitochondria. The surface area ratio between the inner (IMM) and outer mitochondrial membranes (OMM) was also significantly increased, reflecting a denser IMM structure (Fig. 6D), which may contribute to the observed improvements in mitochondrial function.

Fig. 6: Early-life exposure of C. elegans to ER stress improves mitochondrial capacity, activates mitophagy and promotes MERCS assembly.

A Mitochondrial content assessed using transgenic day 1 worms pcox-4::gfp following TM treatment. Three independent experiments with 15 animals/group. Scale 275 μm. Mean ± SEM; ***p ≤ 0.001. Student’s t test. B MitoTracker red staining of N2 strain following TM treatment. Three independent experiments were initiated with 15 animals/group. Scale 275 μm. Mean ± SEM; ****p ≤ 0.0001. Student’s t test. C Oxygen consumption of adult day 1 N2 worms following treatment with TM. Data from 3 independent experiments with 8–12 animals per well. Mean ± SEM; * p < 0.05 Student’s t test. D Representative TEM images of sections from day 1 C. elegans body wall muscle cells. Mitochondrial surface area, aspect ratio and IMM/OMM surface area ratio were calculated. Scale 200 nm. Mean ± SEM; *p ≤ 0.05 and **p ≤ 0.01 Student’s t test. E Representative images of the head region of the pmyo-3::TOMM-20::Rosella day 1 reporter strain following TM treatment from 3 independent experiments initiated with 15 animals/group; **p < 0.01 Student’s t test. Scale 75 μm. F Representative TEM images of sections from day 1 C. elegans body wall muscle cells. Representative images of 3 independent experiments initiated with 10 animals/group. Scale 200 nm. Mean ± SEM; **p ≤ 0.01 Student’s t test. G Representative images of day 2, 4 and 6 pmyo-3::mitogfp reporter strain for muscle mitochondrial morphology, classified as either filamentous, intermediate or punctate. Three independent experiments were initiated with 15 animals/condition. Scale 50 μm. n = 3 *p < 0.05 Chi-square.

Mitochondrial turnover was assessed using the pmyo-3::TOMM-20::Rosella reporter strain, containing a pH-sensitive Rosella biosensor composed of a pH-sensitive GFP and a pH-stable RFP to track mitochondrial turnover in body wall muscle [55]. TM-treated worms exhibited a significantly lower GFP/DsRed fluorescence ratio, indicating increased mitophagy and enhanced mitochondrial turnover during adulthood (Fig. 6E). RNAi knockdown of pdr-1 (ortholog of Parkin, regulator of mitochondrial turnover) had no effect on longevity but in combination with TM treatment decreased lifespan compared with TM alone, RNAi knockdown of pdr-1 resulted in a more fragmented mitochondrial network (Supplementary Fig. 3J, K). RNAi knockdown of lgg-1 (ortholog of LC3, required for autophagosome maturation) following TM treatment resulted in no change in lifespan or on mitochondrial morphology (Supplementary Fig. 3H, I). These results indicate activation of mitophagy is required for the increased longevity and changes in mitochondrial morphology following adaptive UPR^ER signalling.

As MERCS are essential for mitochondrial fission, TEM analysis was performed to quantify the surface area of mitochondria in close contact with the ER (<50 nm). TM-treated worms resulted in a marked increase in MERCS surface area compared to controls (Fig. 6F). Mitochondrial morphology was evaluated during ageing using a genetic pmyo-3::mitoGFP reporter, for visualisation of the mitochondrial network from body wall muscle. Images were taken on days 2, 4 and 6 of adulthood and classified as punctate, intermediate or filamentous, depending on the mitochondrial network morphology [56]. Ageing resulted in a progressive shift towards more punctate (fragmented) networks (Fig. 6G). In contrast, TM-treated worms demonstrated a delayed onset of mitochondrial fragmentation, maintaining more filamentous and intermediate networks at all time points assessed (Fig. 6G). In order to investigate whether this response is redox dependent, the antioxidant N-Acetyl Cysteine (NAC) was used. TM treatment during early development in combination with NAC resulted in the repression of lifespan extension and increased mitochondrial fragmentation, indicating the beneficial adaptive UPR response has a redox component (Supplementary Fig. 3P, Q). Together, the data demonstrate that, similar to myoblasts, early-life TM treatment helps preserve mitochondrial network integrity and morphology during ageing, potentially through the formation of MERCS and regulation of mitochondrial turnover.

PEK-1 (UPR^ER) and ATFS-1 (UPR^mt) crosstalk regulates the adaptations promoted by the UPR in C. elegans

To elucidate the mechanisms underlying UPR-mediated mitochondrial and physiological adaptations, we used mutant strains for the UPR^ER and UPR^mt signalling arms to evaluate their response to early-life TM treatment. Both the ire-1(v33) and xbp-1(tm2482) mutant strains were viable. However, TM treatment resulted in developmental arrest at the larval stage (Supplementary Fig. 3A). This phenotype has previously been reported, generation of double mutants of ire-1 or xbp-1 with atf-6 or pek-1 promoted developmental arrest at larvae stage L2 [57]. highlighting the critical role of the IRE-1 arm in the resistance to ER stress. Similar to the N2 strain, treatment of the atf-6 (ok551) mutant strain with TM resulted in increased longevity and stress resistance to sodium arsenite but not paraquat but increased MitoTracker Red staining (Supplementary Fig. 5B). Interestingly, following TM treatment, atf-6 mutants exhibited a reduction in size at day 1 of adulthood, implying delayed development (Supplementary Fig. 5B). As the increased longevity and survival following TM treatment were also observed in N2 strain (Fig. 4A, G, H), it would suggest they are independent of ATF-6 signalling. Following TM treatment of the PEK-1 loss-of-function mutant strain (pek-1 (ok275)), there was a decrease in lifespan (Fig. 7A), resistance to paraquat was reduced but resistance to sodium arsenite was unaltered (Supplementary Fig. 5C). There was a decrease in MitoTracker Red fluorescence intensity in the TM-treated pek-1 mutants (Fig. 7B). The pek-1 mutant strain also had a reduction in size following TM treatment (Supplementary Fig. 5C). TM treatment of pek-1 mutant strain produced an opposite phenotype compared to the N2 strain, highlighting its importance for this adaptive response. TM treatment of ATFS-1 mutant (atfs-1 (tm4525)) also exhibited a decrease in lifespan (Fig. 7C); however, resistance to oxidative stressors was unaltered (Supplementary Fig. 5D). The ΔΨm of the TM-treated atfs-1 mutant strain decreased following TM treatment (Fig. 7D). Interestingly, TM-treated atfs-1 mutant exhibited no differences in size compared to the control group (Supplementary Fig. 5D). The results highlight that TM treatment of the atfs-1 mutant strain had similar results to the pek-1 mutant and an opposite phenotype to N2 WT strain, highlighting its importance for this adaptive response.

Fig. 7: Adaptations to early-life adaptive UPR^ER in C. elegans depend on PEK-1 and ATFS-1 crosstalk.

A Lifespan analysis of pek-1(ok275) strain following treatment with TM. Kaplan–Meier survival plots of two independent experiments initiated with 100 animals/group, ****p ≤ 0.0001 Log-rank (Mantel-Cox) test. B MitoTracker Red images of TM-treated day 1 pek-1(ok275) worms. Scale 275 μm. Mean ± SEM; ****p ≤ 0.0001 Student’s t test. C Lifespan analysis of atfs-1(tm4525) following treatment with TM. Kaplan–Meier survival plots of two independent experiments initiated with 100 animals/group, ****p ≤ 0.0001 Log-rank (Mantel-Cox) test. D MitoTracker Red images of TM-treated adult day 1 atfs-1(tm4525) worms. Scale 275 μm. Mean ± SEM; **** p ≤ 0.0001 Student’s t test. E Lifespan assay of N2 Wild-type, pek-1(ok275), atfs-1(tm4525) and pek-1;atfs-1 worms following TM treatment Kaplan–Meier survival plots of two independent experiments initiated with 100 animals per group. F Mean lifespan of N2, pek-1(ok275), atfs-1(tm4525) and pek-1;atfs-1 strains. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 One-way ANOVA. G MitoTracker Red images of day1 N2, pek-1(ok275), atfs-1 (tm4525) and pek-1;atfs-1 strains. Data mean SEM of 45 animals/assay. *** p ≤ 0.001, ****p ≤ 0.0001 One-way ANOVA. H Images of pmyo-3::mitogfp reporter strain adult day4 N2 WT, pek-1(ok275), atfs-1(tm4525) and pek-1;atfs-1 backgrounds. 3 independent experiments with 15 animals/condition, n = 3; Scale 12 μm. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 Chi-square. I CeleST physical fitness parameters at day 1 following TM treatment of N2 WT, pek-1, atfs-1 and pek-1;atfs-1 strains. Data from 3 independent experiments initiated with at least 10 animals per condition. Mean ± SEM; **p ≤ 0.01, ***p ≤ 0.001 One-way ANOVA. J CeleST physical fitness parameters that increase with age; average fitness parameters at day 1 following TM treatment of N2 WT, pek-1, atfs-1 and pek-1;atfs-1 mutant strains. Data from three independent experiments initiated with at least 10 animals/conditions. Mean ± SEM; **p ≤ 0.01 and ****p ≤ 0.0001 One-way ANOVA.

A double pek-1;atfs-1 mutant was generated to clarify the possible interaction of these signalling pathways and potential crosstalk of the UPR^ER and UPR^mt. The phenotypic effects of TM treatment in the N2 wild-type strain, pek-1, atfs-1 and pek-1;atfs-1 strains were determined. All mutant strains had decreased lifespan compared to the WT group which had increased longevity (Fig. 7E, F, Supplementary Table 1). Interestingly, TM increased the size of N2 worms, but this effect was reversed in the pek-1 mutant and absent in the atfs-1 mutant (Supplementary Fig. 5E). The pek-1;atfs-1 double mutant exhibited a more severe reduction in body size than either single mutant, both under basal conditions and following TM treatment (Supplementary Fig. 5E). All mutant strains treated with TM had decreased resistance to sodium arsenite and paraquat compared to N2 strain (Supplementary Fig. 5E, Supplementary Tables 2, 3).

Mitochondrial membrane potential was significantly reduced in both the atfs-1 and pek-1;atfs-1 mutants compared to N2, while no differences were observed between the untreated N2 and the pek-1 mutant strain (Fig. 7G). TM treatment only increased mitochondrial membrane potential in N2 WT worms, with all mutants displaying lower MitoTracker Red staining post-TM treatment (Fig. 7G). To assess mitochondrial morphology in body wall muscle, strains were crossed with the pmyo-3::mitoGFP reporter strain and imaged at day 4 of adulthood. Control N2 WT worms had a balanced mitochondrial network with approximately 20% filamentous, 40% intermediate, and 40% punctate mitochondria. The pek-1 and atfs-1 mutants demonstrated increased punctate or more fragmented mitochondrial network (Fig. 7H). However, the pek-1;atfs-1 double mutant displayed a highly disrupted mitochondrial network, with no filamentous mitochondria present. TM treatment increased the percentage of filamentous mitochondria in N2 WT worms (~25%) and reduced the percentage of mitochondrial punctate (~25%). In contrast, the mitochondrial morphology of pek-1 and atfs-1 single mutants remained unchanged following TM treatment, while the pek-1;atfs-1 mutant exhibited further mitochondrial fragmentation (Fig. 7H). Finally, to assess physiological activity, CeLeST analysis was performed. In untreated conditions, fitness-related parameters were similar between WT, pek-1, atfs-1, and pek-1;atfs-1 mutants, while frailty parameters were slightly higher in the mutant strains (Fig. 7I, J, Supplementary Fig. 3F). Following TM treatment, WT worms had increased wave initiation rate, travel speed and activity index indicating increased fitness, this was not observed in any of the mutant strains (Fig. 7, Supplementary Fig. 3F). To dissect the mechanistic basis of this crosstalk we evaluated the cellular response to early-life ER stress. Downstream markers of the UPR^ER and UPR^mt (hsp-4, a canonical UPR^ER target, and hsp-6, a mitochondrial chaperone and target of ATFS-1) exhibited a clear increase in both following TM treatment in the N2 strain. However, mutant strains pek-1(-), atfs-1(-) and pek-1(-);atfs-1(-) did not increase hsp-4 or hsp-6 following TM treatment suggesting both PEK-1 and ATFS-1 are required for adaptive UPR activation (Supplementary Fig. 5G).

Together, these results highlight the critical roles of PEK-1 and ATFS-1 in regulating lifespan, stress resistance and mitochondrial dynamics. The results indicate that under mild ER stress conditions, PEK-1 from the UPR^ER establishes crosstalk with ATFS-1 from the UPR^mt pathway to promote increased lifespan, improved healthspan, enhanced stress resistance and greater mitochondrial function. Moreover, based on the gene expression profile of UPR markers, the slight increase in these markers with the TM treatment elicit an adaptive UPR activation, whereas the more drastic activation of the markers in the AMG + TM group could indicate an induction of maladaptive UPR signalling.

In summary, the data presented using both an in vitro myogenesis model and in vivo whole organism C. elegans, reveals that adaptive UPR^ER signalling through PERK and UPR^mt, induces the assembly of MERCS and regulates mitochondrial adaptations following a low dose of an ER stressor at an early developmental stage. These adaptations promote myogenesis and extension of lifespan in C. elegans by enhancing organelle turnover and mitochondrial function, demonstrating the essential crosstalk between ER and mitochondrial stress responses in maintaining cellular and organismal homeostasis under physiological stress conditions.

Continue Reading

November 1, 2025
Losses Worsening 49.3% Per Year, Revenue Forecast to Trail Market Heading Into Earnings
Xerox Holdings (XRX) remains in the red, with net losses worsening at a steep rate of 49.3% per year over the past five years. While revenue is forecast to grow 9.1% annually, that is still behind the US market’s 10.3% pace, and there is not enough data to say if earnings growth will beat those averages anytime soon.

See our full analysis for Xerox Holdings.

Next up, we will see how the latest financial numbers compare against the core narratives investors follow on Simply Wall St. This will highlight where the story aligns or where perceptions might shift.

See what the community is saying about Xerox Holdings

NasdaqGS:XRX Earnings & Revenue History as at Nov 2025

Analysts forecast Xerox’s profit margins will climb sharply from -21.2% today to 31.8% in three years, signaling a dramatic turnaround in bottom-line performance if cost savings and growth efforts succeed.

Consensus narrative notes that operating model changes and recent acquisitions are expected to boost efficiencies and shift margins higher.

Over 100 reinvention initiatives and integration of ITsavvy and Lexmark aim to deliver significant cost savings, confirming the focus on margin recovery.

However, declining sales force productivity and print segment rationalization may erode these gains if market share is not regained, putting upward margin trajectory at risk.

Xerox trades at $3.32 per share, which is deeply discounted versus its DCF fair value estimate of $17.01, as well as its already low Price-To-Sales Ratio of 0.1x compared to the industry’s 1.9x.

Consensus narrative highlights that the primary rewards hinge on relative value. Investors see the discount as potentially attractive but are wary because deteriorating profitability and weak financial health could prevent the stock from reaching intrinsic value.

With continued losses and a dividend that is not considered sustainable, even a low valuation may not draw investors until operational performance visibly stabilizes.

The market’s focus remains on whether management’s initiatives can close the fair value gap by delivering sustained gains.

The analyst consensus target for Xerox is $4.50 per share, which is 36% above the current price, but assumes revenue will reach $7.7 billion and earnings will hit $2.5 billion by July 2028.

According to the consensus narrative, for this upside to materialize, Xerox must achieve not just higher revenues but also a PE ratio turnaround from -0.5x today to 0.8x by 2028.

The bullish scenario relies on new business signings and full realization of cost savings, but integration risks from acquisitions and a shrinking finance receivables book underline that execution risk is high.

Analyst agreement on forecasts is strong, yet bears could find support if organizational changes fail to reverse ongoing revenue declines.
See how the consensus view explains these crosswinds and the impact for future investors. 📊 Read the full Xerox Holdings Consensus Narrative.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Xerox Holdings on Simply Wall St. Add the company to your watchlist or portfolio so you’ll be alerted when the story evolves.

Think you interpret the numbers another way? Share your perspective and shape your own narrative in just a few minutes. Do it your way.

A great starting point for your Xerox Holdings research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.

Xerox’s deteriorating profitability, ongoing net losses, and questions around financial health make its future recovery far from certain.

If you want more resilient investments, focus on companies demonstrating strong balance sheets and stability with solid balance sheet and fundamentals stocks screener (1984 results). These companies are built to weather uncertainty.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include XRX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Continue Reading
November 1, 2025
Evaluating Valuation After Q3 Earnings Beat, Dividend Hold, and Canadian Acquisition

Rush Enterprises (RUSH.A) just posted third quarter results that outpaced expectations on both revenue and earnings per share. The company continues to navigate a tough market in new truck sales, but the performance in aftermarket and leasing has helped cushion the blow.

See our latest analysis for Rush Enterprises.

Despite a string of positive developments such as beating earnings estimates, announcing a new acquisition in Canada, and maintaining its dividend, Rush Enterprises’ share price has been under pressure, posting a 1-year total shareholder return of -12.87%. Meanwhile, its long-term five-year total shareholder return stands at a robust 119%. Recent price momentum has faded, suggesting the market remains cautious about near-term headwinds but recognizes the company’s long-term value creation.

If you’re interested in seeing what else might be gaining traction in related sectors, now is the perfect moment to broaden your search and discover See the full list for free.

With shares lagging despite solid long-term returns and new initiatives, investors may wonder whether Rush Enterprises is trading at a compelling discount or if the market is already factoring in any rebound in future truck demand.

With Rush Enterprises closing at $49.41 compared to a widely followed narrative fair value of $60.00, the stock stands out for those seeking value among commercial vehicle retailers. The difference between current price and narrative value shines a spotlight on what underpins this estimate.

Extended regulatory and trade policy uncertainty is causing customers to delay new vehicle purchases, leading to aging truck fleets that require increased parts and service work. This supports stable or rising revenue and margins from Rush’s high-margin aftermarket business in the near term, which already accounts for over 60% of gross profit.

Read the complete narrative.

Wondering what drives this bold valuation gap? The secret mix: revenue stream shifts, new margin records, and a forecast that could surprise the entire transportation sector. Dig into the details behind these assumptions and see why the consensus is betting on a future far brighter than the recent past.

Result: Fair Value of $60.00 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, persistent regulatory uncertainty or a prolonged “freight recession” could strain both truck sales and aftermarket revenue. This would challenge the current optimism in forecasts.

Find out about the key risks to this Rush Enterprises narrative.

If you see the story differently or want to reach your own conclusions, you can quickly build your personalized narrative from the data in just a few minutes. Do it your way

A great starting point for your Rush Enterprises research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Take control of your portfolio and gain an edge by researching stocks that align with your goals. The right ideas can make all the difference in seizing opportunities ahead of the crowd.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include RUSHA.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Continue Reading

November 1, 2025
CommScope (COMM) Returns to Profitability, but One-Off Loss Highlights Risks to Bullish Narratives
CommScope Holding Company (COMM) posted a transition into profitability over the twelve months ending September 30, 2025, despite a one-off loss of $45.9 million. While the company delivered earnings growth of 5.9% per year over the past five years and recently turned a positive net profit margin, the outlook is less upbeat. Earnings are projected to decline by 159% per year going forward, with annual revenue growth expected at 9.7%, trailing the wider U.S. market’s 10.4% pace. Investors weighing the latest results will note value signals from the company’s price-to-earnings ratio of 13.1x and trading price below fair value, but future profit risks remain front and center.

See our full analysis for CommScope Holding Company.

Next, we’ll set the latest earnings numbers against the most widely followed narratives for CommScope, highlighting where the story aligns and where it diverges.

See what the community is saying about CommScope Holding Company

NasdaqGS:COMM Earnings & Revenue History as at Nov 2025

CommScope’s DCF fair value is $56.73, while the actual share price is just $17.30, showing an implied discount of over 65% compared to the modeled fundamental valuation.

According to the analysts’ consensus view, the company’s shares trade at a price-to-earnings ratio of 13.1x, well below the U.S. communications industry average of 32x. This

strongly supports the argument that CommScope offers material value upside, especially since it’s also trading below fair value and the peer average of 24.5x.

challenges skepticism about the company’s negative growth outlook, as the valuation gap may already reflect future risk concerns.

Consensus analysts anticipate revenues to reach $6.7 billion and earnings to come in at $139.1 million by 2028, suggesting that the current market price leaves significant room for rerating if those forecasts materialize.

Curious how numbers become stories that shape markets? Explore Community Narratives 📊 Read the full CommScope Holding Company Consensus Narrative.

The completed sale of the CCS business is designed to eliminate company debt and preferred equity, reduce interest expense, and free up significant excess cash for shareholder returns.

Consensus narrative points out that this capital structure change could directly strengthen CommScope’s financial resilience, but leaves the company more reliant on the less predictable ANS and RUCKUS segments going forward. This

raises the stakes for execution in new growth initiatives, since legacy enterprise fiber revenue streams are no longer present to smooth volatility.

indicates that while short-term financial health might improve, long-term revenue stability could be more difficult to achieve given greater exposure to cyclical and customer-concentrated businesses.
Analysts expect CommScope’s revenues to grow 12.3% a year over the next three years, outpacing long-term company forecasts and maintaining momentum thanks to strong demand in ANS (advanced networking) and RUCKUS (enterprise Wi-Fi) products.

Consensus narrative underlines that innovation, especially through DOCSIS 4.0 deployments and rapid adoption of Wi-Fi 7 in enterprise solutions, supports top-line growth and margin improvement. However,

the remaining businesses are more project-driven and cyclical, heightening risk if major customer investments slow or upgrade cycles shift.

sustained improvement in software and subscription revenue is necessary to offset volatility and defend margins as competition increases.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for CommScope Holding Company on Simply Wall St. Add the company to your watchlist or portfolio so you’ll be alerted when the story evolves.

Have a unique take on the figures? Put your viewpoint into context, craft your perspective, and share your own narrative in just a few minutes. Do it your way

A great starting point for your CommScope Holding Company research is our analysis highlighting 3 key rewards and 5 important warning signs that could impact your investment decision.

CommScope’s future is clouded by its exposure to cyclical, project-driven segments and heightened revenue volatility after the sale of its more stable business lines.

If you’re looking for companies delivering steadier results through unpredictable markets, focus your search on those with consistent performance like stable growth stocks screener (2103 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include COMM.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Continue Reading
November 1, 2025
From fast food to beverage giants, brands see rising income inequality among customers

The most common refrain so far this corporate earnings season is that the U.S. economy is increasingly divided between wealthy consumers and everyone else.

While many Americans tighten their belts amid rising costs and a weakening job market, a fortunate few are still spending freely, insulated by a financial cushion of stock market gains and years of rising home values.

The split is having an outsize impact on consumer-facing companies, but those effects aren’t being felt evenly across brands.

McDonald’s CEO Chris Kempczinski said the “two-tier economy” was a major factor in the fast-food giant’s decision to revive its “Extra Value Meal” combos last month.

“Traffic for lower-income consumers is down double digits,” Kempczinski told CNBC in September. “We needed to step in.”

Coca-Cola’s chief operating officer, Henrique Braun, said the company continued to see “divergency in spending between the income groups” last quarter. “The pressure on middle- and low-end-income consumers is still there.”

The widening K

The U.S. economy has been turning more “K”-shaped for decades, with the high-earner cohort doing better and better while others fall further down the economic ladder.

In 1989, the top 10% of U.S. wealth holders already controlled about 61% of the total wealth in the economy, according to Federal Reserve data. Today, it’s about 67%.

While inequality has grown throughout this period, its rate of growth has ebbed and risen.

For example, signs of bifurcation blared louder during the first six months of the Covid-19 pandemic. As the stock market began to recover its early losses, huge parts of the economy remained shut down.

But these signs receded somewhat in the following years, as government stimulus checks and loan-payment forbearance helped boost the fortunes of lower-income households.

A woman wears a mask in New York on Aug. 6, 2020, amid the Covid-19 pandemic.Cindy Ord / Getty Images

Five years on, worrying signals of inequality are roaring back into view. This time, the cracks appear to be hardening.

Average worker pay only barely outpaces inflation — which remains above the Federal Reserve’s 2% target. But the pace of that wage growth is higher for salaried workers than for those paid by the hour, according to data from the Atlanta Federal Reserve.

For nearly all workers, the employment outlook is uncertain, with mass layoffs in the news and AI doing work that people used to do.

“While upper-income consumers are doing great and benefiting from the wealth effect of owning their home and having a stock portfolio, anyone renting or who doesn’t own stocks is not,” said Peter Boockvar, chief investment officer at OnePoint BFG Wealth Partners. “At best, their wages are only keeping up. They’re doing a lot of running in place.”

Two kinds of consumers

The same K shape that characterizes widening income inequality is reflected in consumer spending.

As a result, the volume of companies reporting evidence of a two-tiered economy among their customers surged in recent weeks.

Chipotle CEO Scott Boatwright said the restaurant chain had seen the divide among its customers deepen just in the past few months.

“Earlier this year, as consumer sentiment declined sharply, we saw a broad-based pullback in frequency [of restaurant visits] across all income” levels, he said on Chipotle’s earnings call Wednesday.

An empty patio at a restaurant in Dayton, Ohio, on Oct. 21, 2025.Kyle Grillot / Bloomberg via Getty Images file

“Since then, the gap has widened, with low- to middle-income guests further reducing frequency” of their visits, he said.

Younger adults ages 25 to 35 are being particularly hard hit, said Boatwright. “This group is facing several headwinds, including unemployment, increased student loan repayment and slower real wage growth.”

It’s not just fast-casual dining that’s feeling the loss of lower-income customers.

On Tuesday, the CEO of snack giant Mondelez said the company saw weakness in its cookie and cracker segment last quarter partly due to “value-seeking consumers increasingly turning to discounters and club stores.”

Yet a decline in consumers willing to pay for name-brand snacks like Oreos and Chips Ahoy is only part of the challenge, said chief executive Dirk Van de Put.

“Higher-income consumers increasingly are choosing premium and better-for-you products,” he said, a category that excludes many of Mondelez’s biggest sellers.

The twin issues, he said, were starting to affect the company’s bottom line.

Washington is watching

The growing inequality between a small percentage of consumers and everyone else has caught the attention of the Federal Reserve.

Fed Chair Jerome Powell said he had noticed the surge in consumer-oriented companies reporting split-screen spending patterns.

They “are saying there is a bifurcated economy there, and that consumers at the lower end are struggling and buying less and shifting to lower-cost products,” Powell said Wednesday.

“But at the top, people are spending, at the higher income and wealth,” said Powell. “So, we think there is something there.”

A shopper carries a Louis Vuitton store bag in New York on Sept. 6.Michael Nagle / Bloomberg via Getty Images file

President Donald Trump’s tariffs are part of the equation, too, Fed governor Christopher Waller told CNBC.

Rising prices on a subset of consumer goods hit with tariffs has contributed to a “two-tier” spending scenario where higher-income shoppers had become virtually “price insensitive,” he said.

Meanwhile, lower-income customers will simply “walk out the door” if they see higher prices, Waller said.

The wealthy keep shopping

As lower-income consumers pull back, spending by the top half of the K is increasingly helping to keep the economy humming.

The top 10% of earners account for about half of all consumer spending, according to recent estimates from Moody’s Analytics.

This month, American Express reported that spending by its typically higher-income card holders accelerated by 8%. The number of newly opened “Platinum Card” accounts doubled, partly due to a recent “refresh” of the card’s perks.

Automakers and airlines have likewise expanded their higher-end offerings — with stellar results.

Delta Air Lines now expects sales of premium seats like Comfort-Plus to exceed sales of main cabin seats for the first time, starting next year.

“Premium products used to be loss leaders, and now they’re the highest-margin products,” airline President Glen Hauenstein said on the company’s recent earnings call.

Likewise, Ford and GM both reported booming sales for their largest and most expensive SUVs.

“Today’s auto market is being driven by wealthier households who have access to capital, good loan rates and are propping up the higher end of the market,” Erin Keating, an executive analyst at Cox Automotive, wrote in September.

Beyond consumer spending

Simply looking at consumer behavior may not capture the full financial picture of American households, said Chris Wheat, managing director at JPMorganChase & Co. and president of the the bank’s research institute.

“Just looking at spending, do you really have the full picture of ‘How K-shaped is the K?’” he said. “There are other ways people might be taking advantage of some of the economic growth we’ve been experiencing.”

For example, there are signs that more lower-income households are investing in the stock market than a decade ago.

As of May 2025, the share of people with below-median incomes transferring funds to investment accounts was about five times higher than the average seen between 2010 and 2015, according to data from the JPMorganChase Institute.

The New York Stock Exchange on July 2.Michael Nagle / Bloomberg via Getty Images file

Meanwhile, there is evidence that the K may be flattening for the rich.

Upper-income households face new financial pressures today in a rapidly changing labor market that’s witnessing an unprecedented slowdown in the growth of traditionally higher-paying white-collar jobs.

Credit delinquencies among individuals making $150,000 or more have doubled since 2023, according to credit modeler VantageScore.

During the same period, delinquencies for people making between $45,000 and $150,000 rose 58%, and just 17% for borrowers earning less than $45,000.

The key distinction is annual income versus total wealth, said Rikard Bandebo, VantageScore’s chief economist.

Today, the share of jobs being created that are considered high-income has fallen to its lowest level since at least 2015, he said.

This suggests that even a well-paying job is no longer a reliable source of financial stability compared with owning assets like stocks and real estate.

“We are seeing more people in the U.S. economy struggling to make ends meet — and even seeing people in the higher-income range struggling,” said Bandebo.

“It’s not as simple as income being the differentiator here — it’s wealth being more the driver,” he said.

Continue Reading

November 1, 2025
MicroStrategy Falls Short Of Investment Grade In First S&P Global Credit Ranking

S&P Global Ratings has assigned a so-called junk bond rating to Bitcoin treasury company Strategy (NASDAQ:MSTR).

The ratings firm on Monday assigned Strategy a B- rating with a stable outlook, well below its investment-grade threshold, citing the company’s “high bitcoin concentration, narrow business focus, weak risk-adjusted capitalization, and low U.S. dollar liquidity.”

The rating falls into S&P’s speculative grade. It suggests that the company is “able to service debt for now, but vulnerable to shocks,” VanEck Head of Digital Assets Research Matthew Sigel said in an X post.

Don’t Miss:

Over the past five years, Strategy has shifted its focus from software to issuing debt to accumulate Bitcoin. This has made its stock a proxy for the digital asset for investors who either cannot access the asset directly or do not want to.

S&P said that while Strategy’s debt obligations were denominated in dollars, the company had low dollar liquidity because it does not generate cash and all excess cash is used for Bitcoin purchases and company operations.

S&P said Strategy’s model depended on the company’s ability to raise capital, including to meet debt obligations. The firm warned that ability could be significantly hampered in a Bitcoin downturn, which could lead to a default or the company selling its Bitcoin holdings at lower prices as a last resort.

Trending: Backed by $300M+ in Assets and Microsoft’s Climate Fund, Farmland LP Opens Vital Farmland III to Accredited Investors

Still, Strategy’s credit rating has been celebrated by some proponents. For example, Strategy Chair Michael Saylor on X said that the company was the first Bitcoin treasury firm to receive a major credit rating.

Meanwhile, BTC Inc. CEO David Bailey said, “The market demand for treasury companies is about to explode.”

S&P said it could upgrade Strategy’s rating if the company improved its dollar liquidity, reduced its reliance on convertible debt and continued to demonstrate a strong ability to raise capital even in Bitcoin downturns.

However, an upgrade is unlikely in the next 12 months, S&P added.

Read Next:

Continue Reading

November 1, 2025
Conversion of ADRs into Ordinary Shares listed on the NYSE

On September 24, 2025, the Company’s Board of Directors approved the project to convert American Depositary Receipts (ADRs) into ordinary shares listed on the New York Stock Exchange (NYSE).

With this project, TotalEnergies is adapting to the evolution of its shareholder base, which has become increasingly weighted toward North America. In addition, the Conversion will remove ADR frictions, foster access to additional Assets Under Management (AUM) among institutional investment funds and enhance trading liquidity.

The Company has launched on October 30, 2025 the termination of the deposit agreement between TotalEnergies, JP Morgan Chase Bank, N.A. (the depositary), and the ADR holders governing the ADR program.

Upon termination of the deposit agreement, each outstanding ADR will be cancelled and an ordinary share listed on the NYSE will be delivered. The conversion of the ADRs into ordinary shares listed on the NYSE is expected to become effective from December 8, 2025.

General information regarding the listing of TotalEnergies ordinary shares on the NYSE is available online: Expected Timetable and Frequently Asked Questions.

Continue Reading

November 1, 2025
Innovative gene engineering and drug delivery systems for dendritic cells in cancer immunotherapy | Journal of Biomedical Science
Yang YL, Yang F, Huang ZQ, Li YY, Shi HY, Sun Q, et al. T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems. Front Immunol. 2023;14:1199173.

Article
PubMed
PubMed Central
CAS

Google Scholar
Shen X, Zhou S, Yang Y, Hong T, Xiang Z, Zhao J, et al. TAM-targeted re-education for enhanced cancer immunotherapy: mechanism and recent progress. Front Oncol. 2022;12:1034842.

Article
PubMed
PubMed Central
CAS

Google Scholar
Kim SK, Cho SW. The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment. Front Pharmacol. 2022;13:868695.

Article
PubMed
PubMed Central
CAS

Google Scholar
Bai R, Cui J. Development of immunotherapy strategies targeting tumor microenvironment is fiercely ongoing. Front Immunol. 2022;13:890166.

Article
PubMed
PubMed Central
CAS

Google Scholar
Bol KF, Schreibelt G, Gerritsen WR, De Vries IJ, Figdor CG. Dendritic cell–based immunotherapy: state of the art and beyond. Clin Cancer Res. 2016;22(8):1897–906.

Article
PubMed
CAS

Google Scholar
Tai Y, Chen M, Wang F, Fan Y, Zhang J, Cai B, et al. The role of dendritic cells in cancer immunity and therapeutic strategies. Int Immunopharmacol. 2024;128:111548.

Article
PubMed
CAS

Google Scholar
Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7–24.

Article
PubMed
CAS

Google Scholar
Yu J, Sun H, Cao W, Song Y, Jiang Z. Research progress on dendritic cell vaccines in cancer immunotherapy. Exp Hematol Oncol. 2022;11(1):3.

Article
PubMed
PubMed Central
CAS

Google Scholar
Taefehshokr S, Parhizkar A, Hayati S, Mousapour M, Mahmoudpour A, Eleid L, et al. Cancer immunotherapy: Challenges and limitations. Pathology-Research and Practice. 2022;229:153723.

Article
PubMed
CAS

Google Scholar
Perez CR, De Palma M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat Commun. 2019;10(1):5408.

Article
PubMed
PubMed Central

Google Scholar
Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012;12(8):557–69.

Article
PubMed
CAS

Google Scholar
Wakim LM, Bevan MJ. Cross-dressed dendritic cells drive memory CD8⁺ T-cell activation after viral infection. Nature. 2011;471(7340):629–32.

Article
PubMed
PubMed Central
CAS

Google Scholar
Marino J, Babiker-Mohamed MH, Crosby-Bertorini P, Paster JT, LeGuern C, Germana S, Abdi R, Uehara M, Kim JI, Markmann JF, Tocco G. Donor exosomes rather than passenger leukocytes initiate alloreactive T cell responses after transplantation. Sci Immunol. 2016;1(1):aaf8759.
Saccheri F, Pozzi C, Avogadri F, Barozzi S, Faretta M, Fusi P, Rescigno M. Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitumor immunity. Sci Transl Med. 2010;2(44):44ra57.
Mendoza-Naranjo A, Saéz PJ, Johansson CC, Ramírez M, Mandakovic D, Pereda C, et al. Functional gap junctions facilitate melanoma antigen transfer and cross-presentation between human dendritic cells. J Immunol. 2007;178(11):6949–57.

Article
PubMed
CAS

Google Scholar
Roche PA, Furuta K. The ins and outs of MHC class II-mediated antigen processing and presentation. Nat Rev Immunol. 2015;15(4):203–16.

Article
PubMed
PubMed Central
CAS

Google Scholar
Wang GZ, Tang XD, Lü MH, Gao JH, Liang GP, Li N, et al. Multiple antigenic peptides of human heparanase elicit a much more potent immune response against tumors. Cancer Prev Res. 2011;4(8):1285–95.

Article
CAS

Google Scholar
Sika-Paotonu D. Increasing the potency of dendritic cell-based vaccines for the treatment of cancer (Doctoral dissertation, Te Herenga Waka-Victoria University of Wellington). 2014.
Sánchez-León ML, Jiménez-Cortegana C, Cabrera G, Vermeulen EM, de la Cruz-Merino L, Sánchez-Margalet V. The effects of dendritic cell-based vaccines in the tumor microenvironment: impact on myeloid-derived suppressor cells. Front Immunol. 2022;13:1050484.

Article
PubMed
PubMed Central

Google Scholar
MacDonald KP, Munster DJ, Clark GJ, Dzionek A, Schmitz J, Hart DN. Characterization of human blood dendritic cell subsets. Blood J Am Soc Hematol. 2002;100(13):4512–20.

CAS

Google Scholar
Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell. 2001;106(3):259–62.

Article
PubMed
CAS

Google Scholar
Böttcher JP, Sousa CR. The role of type 1 conventional dendritic cells in cancer immunity. Trends Cancer. 2018;4(11):784–92.
Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013;31(1):563–604.

Article
PubMed
CAS

Google Scholar
Schlitzer A, McGovern N, Ginhoux F. Dendritic cells and monocyte-derived cells: two complementary and integrated functional systems. Semin Cell Dev Biol. 2015;41:9–22.

Article
PubMed
CAS

Google Scholar
Lee KW, Yam JW, Mao X. Dendritic cell vaccines: a shift from conventional approach to new generations. Cells. 2023;12(17):2147.

Article
PubMed
PubMed Central
CAS

Google Scholar
Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW. Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer. Cancer Interdisc Int J Am Cancer Soc. 2009;115(16):3670–9.
Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011;17(11):3520–6.

Article
PubMed

Google Scholar
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.

Article
PubMed
CAS

Google Scholar
Ratzinger G, Baggers J, de Cos MA, Yuan J, Dao T, Reagan JL, et al. Mature human Langerhans cells derived from CD34⁺ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells. J Immunol. 2004;173(4):2780–91.

Article
PubMed
CAS

Google Scholar
Chung DJ, Carvajal RD, Postow MA, Sharma S, Pronschinske KB, Shyer JA, et al. Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: results of a phase I vaccine trial. Oncoimmunology. 2018;7(1):e1372081.

Article

Google Scholar
Laoui D, Keirsse J, Morias Y, Van Overmeire E, Geeraerts X, Elkrim Y, et al. The tumor microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumor immunity. Nat Commun. 2016;7(1):13720.

Article
PubMed
PubMed Central
CAS

Google Scholar
Mastelic-Gavillet B, Balint K, Boudousquie C, Gannon PO, Kandalaft LE. Personalized dendritic cell vaccines—recent breakthroughs and encouraging clinical results. Front Immunol. 2019;11(10):766.

Article

Google Scholar
Tel J, Benitez-Ribas D, Hoosemans S, Cambi A, Adema GJ, Figdor CG, et al. DEC-205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells. Eur J Immunol. 2011;41(4):1014–23.

Article
PubMed
CAS

Google Scholar
Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8⁺ T cell tolerance. J Exp Med. 2002;196(12):1627–38.

Article
PubMed
PubMed Central
CAS

Google Scholar
Naseri M, Bozorgmehr M, Zöller M, Ranaei Pirmardan E, Madjd Z. Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy. Oncoimmunology. 2020;9(1):1779991.

Article
PubMed
PubMed Central

Google Scholar
Gu L, Mooney DJ. Biomaterials and emerging anticancer therapeutics: engineering the microenvironment. Nat Rev Cancer. 2016;16(1):56–66.

Article
PubMed
PubMed Central
CAS

Google Scholar
Ali OA, Huebsch N, Cao L, Dranoff G, Mooney DJ. Infection-mimicking materials to program dendritic cells in situ. Nat Mater. 2009;8(2):151–8.

Article
PubMed
PubMed Central
CAS

Google Scholar
Gentile P, Chiono V, Carmagnola I, Hatton PV. An overview of poly (lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering. Int J Mol Sci. 2014;15(3):3640–59.

Article
PubMed
PubMed Central
CAS

Google Scholar
Bencherif SA, Sands RW, Bhatta D, Arany P, Verbeke CS, Edwards DA, et al. Injectable preformed scaffolds with shape-memory properties. Proc Natl Acad Sci. 2012;109(48):19590–5.

Article
PubMed
PubMed Central
CAS

Google Scholar
Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019;20(8):1083–97.

Article
PubMed
CAS

Google Scholar
Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8(1):e000337.

Article
PubMed
PubMed Central

Google Scholar
Vedunova M, Turubanova V, Vershinina O, Savyuk M, Efimova I, Mishchenko T, et al. DC vaccines loaded with glioma cells killed by photodynamic therapy induce Th17 antitumor immunity and provide a four-gene signature for glioma prognosis. Cell Death Dis. 2022;13(12):1062.

Article
PubMed
PubMed Central
CAS

Google Scholar
Wang X, Ji J, Zhang H, Fan Z, Zhang L, Shi L, et al. Stimulation of dendritic cells by DAMPs in ALA-PDT treated SCC tumor cells. Oncotarget. 2015;6(42):44688.

Article
PubMed
PubMed Central

Google Scholar
Gu YZ, Zhao X, Song XR. Ex vivo pulsed dendritic cell vaccination against cancer. Acta Pharmacol Sin. 2020;41(7):959–69.

Article
PubMed
PubMed Central
CAS

Google Scholar
Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, De Wilt JH, et al. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res. 2012;18(19):5460–70.

Article
PubMed
CAS

Google Scholar
Kreiter S, Selmi A, Diken M, Sebastian M, Osterloh P, Schild H, et al. Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J Immunol. 2008;180(1):309–18.

Article
PubMed
CAS

Google Scholar
Dannull J, Nair S, Su Z, Boczkowski D, DeBeck C, Yang B, et al. Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood. 2005;105(8):3206–13.

Article
PubMed
CAS

Google Scholar
Tcherepanova IY, Adams MD, Feng X, Hinohara A, Horvatinovich J, Calderhead D, et al. Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion. BMC Mol Biol. 2008;9(1):90.

Article
PubMed
PubMed Central

Google Scholar
Carneiro BA, Zamarin D, Marron T, Mehmi I, Patel SP, Subbiah V, El-Khoueiry A, Grand D, Garcia-Reyes K, Goel S, Martin P. Abstract CT183: first-in-human study of MEDI1191 (mRNA encoding IL-12) plus durvalumab in patients (pts) with advanced solid tumors. Cancer Res. 2022 Jun 15;82(12_Supplement):CT183-.
Pitt JM, André F, Amigorena S, Soria JC, Eggermont A, Kroemer G, et al. Dendritic cell–derived exosomes for cancer therapy. J Clin Investig. 2016;126(4):1224–32.

Article
PubMed
PubMed Central

Google Scholar
Fu C, Peng P, Loschko J, Feng L, Pham P, Cui W, et al. Plasmacytoid dendritic cells cross-prime naive CD8 T cells by transferring antigen to conventional dendritic cells through exosomes. Proc Natl Acad Sci. 2020;117(38):23730–41.

Article
PubMed
PubMed Central
CAS

Google Scholar
Dai Phung C, Pham TT, Nguyen HT, Nguyen TT, Ou W, Jeong JH, et al. Anti-CTLA-4 antibody-functionalized dendritic cell-derived exosomes targeting tumor-draining lymph nodes for effective induction of antitumor T-cell responses. Acta Biomater. 2020;1(115):371–82.

Article

Google Scholar
Mohammadzadeh Y, De Palma M. Boosting dendritic cell nanovaccines. Nat Nanotechnol. 2022;17(5):442–4.

Article
PubMed
CAS

Google Scholar
Chen J, Duan Y, Che J, Zhu J. Dysfunction of dendritic cells in tumor microenvironment and immunotherapy. Cancer Commun. 2024;44(9):1047–70.

Article

Google Scholar
Stevens D, Ingels J, Van Lint S, Vandekerckhove B, Vermaelen K. Dendritic cell-based immunotherapy in lung cancer. Front Immunol. 2021;11:620374.

Article
PubMed
PubMed Central

Google Scholar
Zheng J, Li X, He A, Zhang Y, Yang Y, Dang M, et al. In situ antigen-capture strategies for enhancing dendritic cell-mediated antitumor immunity. J Control Release. 2025;29:113984.

Article

Google Scholar
Ng YH, Chalasani G. Role of secondary lymphoid tissues in primary and memory T-cell responses to a transplanted organ. Transplant Rev. 2010;24(1):32–41.

Article

Google Scholar
Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX, et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol. 2000;164(9):4558–63.

Article
PubMed
CAS

Google Scholar
von Renesse J, Lin MC, Ho PC. Tumor-draining lymph nodes–friend or foe during immune checkpoint therapy? Trends Cancer. 2025.
Böttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, Rogers NC, Sahai E, Zelenay S, Sousa CR. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018;172(5):1022–37.
Alfei F, Ho PC, Lo WL. DCision-making in tumors governs T cell antitumor immunity. Oncogene. 2021;40(34):5253–61.

Article
PubMed
PubMed Central
CAS

Google Scholar
Peng X, He Y, Huang J, Tao Y, Liu S. Metabolism of dendritic cells in tumor microenvironment: for immunotherapy. Front Immunol. 2021;12:613492.

Article
PubMed
PubMed Central
CAS

Google Scholar
McGettrick AF, O’Neill LA. How metabolism generates signals during innate immunity and inflammation. J Biol Chem. 2013;288(32):22893–8.

Article
PubMed
PubMed Central
CAS

Google Scholar
Møller SH, Wang L, Ho PC. Metabolic programming in dendritic cells tailors immune responses and homeostasis. Cell Mol Immunol. 2022;19(3):370–83.

Article
PubMed

Google Scholar
Wculek SK, Khouili SC, Priego E, Heras-Murillo I, Sancho D. Metabolic control of dendritic cell functions: digesting information. Front Immunol. 2019;10:775.

Article
PubMed
PubMed Central
CAS

Google Scholar
Naldini A, Morena E, Pucci A, Miglietta D, Riboldi E, Sozzani S, et al. Hypoxia affects dendritic cell survival: role of the hypoxia-inducible factor-1α and lipopolysaccharide. J Cell Physiol. 2012;227(2):587–95.

Article
PubMed
CAS

Google Scholar
Carraro F, Pucci A, Pellegrini M, Giuseppe Pelicci P, Baldari CT, Naldini A. p66Shc is involved in promoting HIF-1α accumulation and cell death in hypoxic T cells. J Cell Physiol. 2007;211(2):439–47.

Article
PubMed
CAS

Google Scholar
Mortezaee K, Majidpoor J. The impact of hypoxia on immune state in cancer. Life Sci. 2021;286:120057.

Article
PubMed
CAS

Google Scholar
Márquez S, Fernández JJ, Terán-Cabanillas E, Herrero C, Alonso S, Azogil A, et al. Endoplasmic reticulum stress sensor IRE1α enhances IL-23 expression by human dendritic cells. Front Immunol. 2017;8:639.

Article
PubMed
PubMed Central

Google Scholar
Hackstein H, Taner T, Zahorchak AF, Morelli AE, Logar AJ, Gessner A, et al. Rapamycin inhibits IL-4—induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood. 2003;101(11):4457–63.

Article
PubMed
CAS

Google Scholar
Cao W, Manicassamy S, Tang H, Kasturi SP, Pirani A, Murthy N, et al. Toll-like receptor–mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI (3) K-mTOR-p70S6K pathway. Nat Immunol. 2008;9(10):1157–64.

Article
PubMed
PubMed Central
CAS

Google Scholar
Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol. 2007;178(11):7018–31.

Article
PubMed
CAS

Google Scholar
Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med. 2010;16(8):880–6.

Article
PubMed
PubMed Central
CAS

Google Scholar
Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem. 2002;277(26):23111–5.

Article
PubMed
CAS

Google Scholar
Carstensen LS, Lie-Andersen O, Obers A, Crowther MD, Svane IM, Hansen M. Long-term exposure to inflammation induces differential cytokine patterns and apoptosis in dendritic cells. Front Immunol. 2019;10:2702.

Article
PubMed
PubMed Central
CAS

Google Scholar
Hansen M, Andersen MH. The role of dendritic cells in cancer. InSeminars Immunopathol. 2017;39:307–16.

Article
CAS

Google Scholar
Jin HR, Wang J, Wang ZJ, Xi MJ, Xia BH, Deng K, et al. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. J Hematol Oncol. 2023;16(1):103.

Article
PubMed
PubMed Central
CAS

Google Scholar
Giovanelli P, Sandoval TA, Cubillos-Ruiz JR. Dendritic cell metabolism and function in tumors. Trends Immunol. 2019;40(8):699–718.

Article
PubMed
CAS

Google Scholar
Veglia F, Tyurin VA, Mohammadyani D, Blasi M, Duperret EK, Donthireddy L, et al. Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer. Nat Commun. 2017;8(1):2122.

Article
PubMed
PubMed Central

Google Scholar
Caronni N, Simoncello F, Stafetta F, Guarnaccia C, Ruiz-Moreno JS, Opitz B, et al. Downregulation of membrane trafficking proteins and lactate conditioning determine loss of dendritic cell function in lung cancer. Can Res. 2018;78(7):1685–99.

Article
CAS

Google Scholar
Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, Chopra S, Perales-Puchalt A, Song M, et al. ER stress sensor XBP1 controls antitumor immunity by disrupting dendritic cell homeostasis. Cell. 2015;161(7):1527–38.

Article
PubMed
PubMed Central
CAS

Google Scholar
Song M, Cubillos-Ruiz JR. Endoplasmic reticulum stress responses in intratumoral immune cells: implications for cancer immunotherapy. Trends Immunol. 2019;40(2):128–41.

Article
PubMed
CAS

Google Scholar
Zhu C, Dixon KO, Newcomer K, Gu G, Xiao S, Zaghouani S, Schramm MA, Wang C, Zhang H, Goto K, Christian E. Tim-3 adaptor protein Bat3 is a molecular checkpoint of T cell terminal differentiation and exhaustion. Sci Adv. 2021;7(18):eabd2710.
Cubillos-Ruiz JR, Bettigole SE, Glimcher LH. Tumorigenic and immunosuppressive effects of endoplasmic reticulum stress in cancer. Cell. 2017;168(4):692–706.

Article
PubMed
PubMed Central
CAS

Google Scholar
Werfel TA, Cook RS. Efferocytosis in the tumor microenvironment. InSeminars in immunopathology. 2018;40(6).
Gottfried E, Kunz-Schughart LA, Ebner S, Mueller-Klieser W, Hoves S, Andreesen R, et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood. 2006;107(5):2013–21.

Article
PubMed
CAS

Google Scholar
Wobser M, Voigt H, Houben R, Eggert AO, Freiwald M, Kaemmerer U, et al. Dendritic cell based antitumor vaccination: impact of functional indoleamine 2, 3-dioxygenase expression. Cancer Immunol Immunother. 2007;56:1017–24.

Article
PubMed
CAS

Google Scholar
Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol. 2003;4(12):1206–12.

Article
PubMed
CAS

Google Scholar
Munn DH, Mellor AL. IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol. 2016;37(3):193–207.

Article
PubMed
PubMed Central
CAS

Google Scholar
McDonnell AM, Robinson BW, Currie AJ. Tumor antigen cross-presentation and the dendritic cell: where it all begins? J Immunol Res. 2010;2010(1):539519.

Article

Google Scholar
Xiao Z, Wang R, Wang X, Yang H, Dong J, He X, et al. Impaired function of dendritic cells within the tumor microenvironment. Front Immunol. 2023;27(14):1213629.

Article

Google Scholar
Wu Y, Pu X, Wang X, Xu M. Reprogramming of lipid metabolism in the tumor microenvironment: a strategy for tumor immunotherapy. Lipids Health Dis. 2024;23(1):35.

Article
PubMed
PubMed Central
CAS

Google Scholar
He S, Zheng L, Qi C. Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy. Mol Cancer. 2025;24(1):5.

Article
PubMed
PubMed Central

Google Scholar
Wang H, Zhou F, Qin W, Yang Y, Li X, Liu R. Metabolic regulation of myeloid-derived suppressor cells in tumor immune microenvironment: targets and therapeutic strategies. Theranostics. 2025;15(6):2159.

Article
PubMed
PubMed Central

Google Scholar
Grzywa TM, Sosnowska A, Matryba P, Rydzynska Z, Jasinski M, Nowis D, Golab J. Myeloid cell-derived arginase in cancer immune response. Front Immunol. 2020;11:938.
Wang F, Lou J, Gao X, Zhang L, Sun F, Wang Z, et al. Spleen-targeted nanosystems for immunomodulation. Nano Today. 2023;1(52):101943.

Article

Google Scholar
Cao W, Ramakrishnan R, Tuyrin VA, Veglia F, Condamine T, Amoscato A, et al. Oxidized lipids block antigen cross-presentation by dendritic cells in cancer. J Immunol. 2014;192(6):2920–31.

Article
CAS

Google Scholar
Traversari C, Sozzani S, Steffensen KR, Russo V. LXR-dependent and-independent effects of oxysterols on immunity and tumor growth. Eur J Immunol. 2014;44(7):1896–903.

Article
PubMed
CAS

Google Scholar
Villablanca EJ, Raccosta L, Zhou D, Fontana R, Maggioni D, Negro A, et al. Tumor-mediated liver X receptor-α activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat Med. 2010;16(1):98–105.

Article
PubMed
CAS

Google Scholar
Bosteels V, Maréchal S, De Nolf C, Rennen S, Maelfait J, Tavernier SJ, Vetters J, Van De Velde E, Fayazpour F, Deswarte K, Lamoot A. LXR signaling controls homeostatic dendritic cell maturation. Sci Immunol. 2023;8(83):eadd3955.
Shen M, Jiang X, Peng Q, Oyang L, Ren Z, Wang J, et al. The cGAS-STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications. J Hematol Oncol. 2025;18(1):40.

Article
PubMed
PubMed Central
CAS

Google Scholar
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050–9.

Article
PubMed
CAS

Google Scholar
Yanai H, Ban T, Wang Z, Choi MK, Kawamura T, Negishi H, et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature. 2009;462(7269):99–103.

Article
PubMed
CAS

Google Scholar
Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, et al. Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. 2012;13(9):832–42.

Article
PubMed
PubMed Central
CAS

Google Scholar
Xu MM, Pu Y, Han D, Shi Y, Cao X, Liang H, et al. Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein α signaling. Immunity. 2017;47(2):363–73.

Article
PubMed
PubMed Central
CAS

Google Scholar
Huang CY, Ye ZH, Huang MY, Lu JJ. Regulation of CD47 expression in cancer cells. Transl Oncol. 2020;13(12):100862.

Article
PubMed
PubMed Central

Google Scholar
Sockolosky JT, Dougan M, Ingram JR, Ho CC, Kauke MJ, Almo SC, et al. Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc Natl Acad Sci. 2016;113(19):E2646–54.

Article
PubMed
PubMed Central
CAS

Google Scholar
Ng II, Zhang Z, Xiao K, Ye M, Tian T, Zhu Y, He Y, Chu L, Tang H. Targeting WEE1 in tumor-associated dendritic cells potentiates antitumor immunity via the cGAS/STING pathway. Cell Reports. 2025;44(6).
Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature. 2009;461(7265):788–92.

Article
PubMed
PubMed Central
CAS

Google Scholar
Fu J, Kanne DB, Leong M, Glickman LH, McWhirter SM, Lemmens E, Mechette K, Leong JJ, Lauer P, Liu W, Sivick KE. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med. 2015;7(283):283ra52.
Motedayen Aval L, Pease JE, Sharma R, Pinato DJ. Challenges and opportunities in the clinical development of STING agonists for cancer immunotherapy. J Clin Med. 2020;9(10):3323.

Article
PubMed
PubMed Central

Google Scholar
Spranger S, Dai D, Horton B, Gajewski TF. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 2017;31(5):711–23.

Article
PubMed
PubMed Central
CAS

Google Scholar
Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signaling prevents anti-tumor immunity. Nature. 2015;523(7559):231–5.

Article
PubMed
CAS

Google Scholar
Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, et al. A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments. Nat Med. 2018;24(8):1178–91.

Article
PubMed
PubMed Central
CAS

Google Scholar
Zong J, Keskinov AA, Shurin GV, Shurin MR. Tumor-derived factors modulating dendritic cell function. Cancer Immunol Immunother. 2016;65:821–33.

Article
PubMed
PubMed Central
CAS

Google Scholar
Zelenay S, Van Der Veen AG, Böttcher JP, Snelgrove KJ, Rogers N, Acton SE, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015;162(6):1257–70.

Article
PubMed
PubMed Central
CAS

Google Scholar
Tang M, Diao J, Gu H, Khatri I, Zhao J, Cattral MS. Toll-like receptor 2 activation promotes tumor dendritic cell dysfunction by regulating IL-6 and IL-10 receptor signaling. Cell Rep. 2015;13(12):2851–64.

Article
PubMed
CAS

Google Scholar
Nirschl CJ, Suárez-Fariñas M, Izar B, Prakadan S, Dannenfelser R, Tirosh I, et al. IFNγ-dependent tissue-immune homeostasis is co-opted in the tumor microenvironment. Cell. 2017;170(1):127–41.

Article
PubMed
PubMed Central
CAS

Google Scholar
Fu C, Liang X, Cui W, Ober-Blöbaum JL, Vazzana J, Shrikant PA, et al. β-Catenin in dendritic cells exerts opposite functions in cross-priming and maintenance of CD8+ T cells through regulation of IL-10. Proc Natl Acad Sci. 2015;112(9):2823–8.

Article
PubMed
PubMed Central
CAS

Google Scholar
Ramalingam R. Importance of TGF-beta signaling in dendritic cells to maintain immune tolerance. 2012; Doctoral dissertation, The University of Arizona.
Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limón P. The polarization of immune cells in the tumor environment by TGFβ. Nat Rev Immunol. 2010;10(8):554–67.

Article
PubMed
CAS

Google Scholar
Hsu JM, Li CW, Lai YJ, Hung MC. Posttranslational modifications of PD-L1 and their applications in cancer therapy. Can Res. 2018;78(22):6349–53.

Article
CAS

Google Scholar
Zhang L, Nishi H. Transcriptome analysis of Homo sapiens and Mus musculus reveals mechanisms of CD8+ T cell exhaustion caused by different factors. PLoS ONE. 2022;17(9):e0274494.

Article
PubMed
PubMed Central
CAS

Google Scholar
Kagoya Y. Molecular profiles of exhausted T cells and their impact on response to immune checkpoint blockade. Gan to kagaku ryoho. Cancer Chemother. 2022;49(6):609–14.
Verdon DJ, Mulazzani M, Jenkins MR. Cellular and molecular mechanisms of CD8+ T cell differentiation, dysfunction and exhaustion. Int J Mol Sci. 2020;21(19):7357.

Article
PubMed
PubMed Central
CAS

Google Scholar
Mende I, Engleman EG. Breaking self-tolerance to tumor-associated antigens by in vivo manipulation of dendritic cells. InImmunological Tolerance Methods Protocols. 2007;457–468. Totowa, NJ: Humana Press.
Mende I, Engleman EG. Breaking tolerance to tumors with dendritic cell-based immunotherapy. Ann N Y Acad Sci. 2005;1058(1):96–104.

Article
PubMed
CAS

Google Scholar
Gehrcken L, Deben C, Smits E, Van Audenaerde JR. STING agonists and how to reach their full potential in cancer immunotherapy. Adv Sci. 2025;12(17):2500296.

Article

Google Scholar
Pavlovic K, Tristán-Manzano M, Maldonado-Pérez N, Cortijo-Gutierrez M, Sánchez-Hernández S, Justicia-Lirio P, et al. Using gene editing approaches to fine-tune the immune system. Front Immunol. 2020;11:570672.

Article
PubMed
PubMed Central
CAS

Google Scholar
Xu Y, Chen C, Guo Y, Hu S, Sun Z. Effect of CRISPR/Cas9-edited PD-1/PD-L1 on tumor immunity and immunotherapy. Front Immunol. 2022;13:848327.

Article
PubMed
PubMed Central
CAS

Google Scholar
Allemailem KS, Alsahli MA, Almatroudi A, Alrumaihi F, Al Abdulmonem W, Moawad AA, Alwanian WM, Almansour NM, Rahmani AH, Khan AA. Innovative strategies of reprogramming immune system cells by targeting CRISPR/Cas9-based genome-editing tools: a new era of cancer management. Int J Nanomed. 2023; 5531–59.
Becker AM. Exploring the modulation and development of type 3 dendritic cells in cancer and autoimmunity. Sl:Sn; 2023.
Turnis ME, Rooney CM. Enhancement of dendritic cells as vaccines for cancer. Immunotherapy. 2010;2(6):847–62.

Article
PubMed
CAS

Google Scholar
Cornel AM, Van Til NP, Boelens JJ, Nierkens S. Strategies to genetically modulate dendritic cells to potentiate antitumor responses in hematologic malignancies. Front Immunol. 2018;9:982.

Article
PubMed
PubMed Central

Google Scholar
Caux C, Massacrier C, Vanbervliet B, Dubois B, Durand I, Cella M, Lanzavecchia A, Banchereau J. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor α: II. Functional analysis. Blood J Am Soc Hematol. 1997;90(4):1458–70.
Kumar J, Kale V, Limaye L. Umbilical cord blood-derived CD11c+ dendritic cells could serve as an alternative allogeneic source of dendritic cells for cancer immunotherapy. Stem Cell Res Ther. 2015;6:1–5.

Article

Google Scholar
Kikuchi T. Genetically modified dendritic cells for therapeutic immunity. Tohoku J Exp Med. 2006;208(1):1–8.

Article
PubMed
CAS

Google Scholar
Rossi A, Dupaty L, Aillot L, Zhang L, Gallien C, Hallek M, et al. Vector uncoating limits adeno-associated viral vector-mediated transduction of human dendritic cells and vector immunogenicity. Sci Rep. 2019;9(1):3631.

Article
PubMed
PubMed Central

Google Scholar
Jost M, Jacobson AN, Hussmann JA, Cirolia G, Fischbach MA, Weissman JS. CRISPR-based functional genomics in human dendritic cells. Elife. 2021;10:e65856.

Article
PubMed
PubMed Central
CAS

Google Scholar
Hutten T, Thordardottir S, Hobo W, Hübel J, van der Waart AB, Cany J, et al. Ex vivo generation of interstitial and langerhans cell-like dendritic cell subset–based vaccines for hematological malignancies. J Immunother. 2014;37(5):267–77.

Article
PubMed
CAS

Google Scholar
Gundry MC, Brunetti L, Lin A, Mayle AE, Kitano A, Wagner D, et al. Highly efficient genome editing of murine and human hematopoietic progenitor cells by CRISPR/Cas9. Cell Rep. 2016;17(5):1453–61.

Article
PubMed
PubMed Central
CAS

Google Scholar
Mao K, Tan H, Cong X, Liu J, Xin Y, Wang J, et al. Optimized lipid nanoparticles enable effective CRISPR/Cas9-mediated gene editing in dendritic cells for enhanced immunotherapy. Acta Pharmaceutica Sinica B. 2025;15(1):642–56.

Article
PubMed
CAS

Google Scholar
Hung KL, Meitlis I, Hale M, Chen CY, Singh S, Jackson SW, et al. Engineering protein-secreting plasma cells by homology-directed repair in primary human B cells. Mol Ther. 2018;26(2):456–67.

Article
PubMed
CAS

Google Scholar
Okada N, Mori N, Koretomo R, Okada Y, Nakayama T, Yoshie O, et al. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction. Gene Ther. 2005;12(2):129–39.

Article
PubMed
CAS

Google Scholar
Alvarez D, Vollmann EH, von Andrian UH. Mechanisms and consequences of dendritic cell migration. Immunity. 2008;29(3):325–42.

Article
PubMed
PubMed Central
CAS

Google Scholar
Jiang A, Bloom O, Ono S, Cui W, Unternaehrer J, Jiang S, et al. Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. Immunity. 2007;27(4):610–24.

Article
PubMed
PubMed Central

Google Scholar
Bonehill A, Tuyaerts S, Van Nuffel AM, Heirman C, Bos TJ, Fostier K, et al. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther. 2008;16(6):1170–80.

Article
PubMed
CAS

Google Scholar
Grünebach F, Kayser K, Weck MM, Müller MR, Appel S, Brossart P. Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4–1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes. Cancer Gene Ther. 2005;12(9):749–56.

Article
PubMed

Google Scholar
De Keersmaecker B, Heirman C, Corthals J, Empsen C, van Grunsven LA, Allard SD, et al. The combination of 4–1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses. J Leukoc Biol. 2011;89(6):989–99.

Article
PubMed

Google Scholar
Boczkowski D, Lee J, Pruitt S, Nair S. Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. Cancer Gene Ther. 2009;16(12):900–11.

Article
PubMed
CAS

Google Scholar
Han D, Liu J, Chen C, Dong L, Liu Y, Chang R, et al. Anti-tumor immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. Nature. 2019;566(7743):270–4.

Article
PubMed
PubMed Central
CAS

Google Scholar
Murphy TL, Murphy KM. Dendritic cells in cancer immunology. Cell Mol Immunol. 2022;19(1):3–13.

Article
PubMed
CAS

Google Scholar
Theisen DJ, Davidson JT IV, Briseño CG, Gargaro M, Lauron EJ, Wang Q, et al. WDFY4 is required for cross-presentation in response to viral and tumor antigens. Science. 2018;362(6415):694–9.

Article
PubMed
PubMed Central
CAS

Google Scholar
Parnas O, Jovanovic M, Eisenhaure TM, Herbst RH, Dixit A, Ye CJ, et al. A genome-wide CRISPR screen in primary immune cells to dissect regulatory networks. Cell. 2015;162(3):675–86.

Article
PubMed
PubMed Central
CAS

Google Scholar
Albrecht V, Hofer TP, Foxwell B, Frankenberger M, Ziegler-Heitbrock L. Tolerance induced via TLR2 and TLR4 in human dendritic cells: role of IRAK-1. BMC Immunol. 2008;9:1–4.

Article

Google Scholar
Zhang Y, Shen S, Zhao G, Xu CF, Zhang HB, Luo YL, et al. In situ repurposing of dendritic cells with CRISPR/Cas9-based nanomedicine to induce transplant tolerance. Biomaterials. 2019;217:119302.

Article
PubMed
CAS

Google Scholar
Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. 2013;31(9):822–6.

Article
PubMed
PubMed Central
CAS

Google Scholar
Tsai SQ, Nguyen N, Zheng Z, Joung JK. High-fidelity CRISPR-Cas9 variants with undetectable genome-wide off-targets. Nature. 2016;529(7587):490–5.

Article
PubMed
PubMed Central

Google Scholar
Xu H, Look T, Prithiviraj S, Lennartz D, Cáceres MD, Götz K, et al. CRISPR/Cas9 editing in conditionally immortalized HoxB8 cells for studying gene regulation in mouse dendritic cells. Eur J Immunol. 2022;52(11):1859–62.

Article
PubMed
CAS

Google Scholar
He M, Roussak K, Ma F, Borcherding N, Garin V, White M, Schutt C, Jensen TI, Zhao Y, Iberg CA, Shah K. CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses. Science. 2023;379(6633):eabg2752.
Groom JR. Regulators of T-cell fate: integration of cell migration, differentiation and function. Immunol Rev. 2019;289(1):101–14.

Article
PubMed
CAS

Google Scholar
Kwon YW, Ahn HS, Lee JW, Yang HM, Cho HJ, Kim SJ, et al. HLA DR genome editing with TALENs in human iPSCs produced immune-tolerant dendritic cells. Stem Cells Int. 2021;2021(1):8873383.

PubMed
PubMed Central

Google Scholar
Menger L, Sledzinska A, Bergerhoff K, Vargas FA, Smith J, Poirot L, et al. TALEN-mediated inactivation of PD-1 in tumor-reactive lymphocytes promotes intratumoral T-cell persistence and rejection of established tumors. Can Res. 2016;76(8):2087–93.

Article
CAS

Google Scholar
Bhardwaj A, Nain V. TALENs—an indispensable tool in the era of CRISPR: a mini review. J Genetic Eng Biotechnol. 2021;19(1):125.

Article

Google Scholar
Hashimoto M, Bacman SR, Peralta S, Falk MJ, Chomyn A, Chan DC, et al. MitoTALEN: a general approach to reduce mutant mtDNA loads and restore oxidative phosphorylation function in mitochondrial diseases. Mol Ther. 2015;23(10):1592–9.

Article
PubMed
PubMed Central
CAS

Google Scholar
Hivroz C, Chemin K, Tourret M, Bohineust A. Crosstalk between T lymphocytes and dendritic cells. Crit Reviews™ Immunol. 2012;32(2).
Rittiner JE, Moncalvo M, Chiba-Falek O, Kantor B. Gene-editing technologies paired with viral vectors for translational research into neurodegenerative diseases. Front Mol Neurosci. 2020;12(13):148.

Article

Google Scholar
Mahfouz MM, Piatek A, Stewart CN Jr. Genome engineering via TALENs and CRISPR/Cas9 systems: challenges and perspectives. Plant Biotechnol J. 2014;12(8):1006–14.

Article
PubMed
CAS

Google Scholar
Tenjo-Castaño F, Montoya G, Carabias A. Transposons and CRISPR: rewiring gene editing. Biochemistry. 2022;62(24):3521–32.

Article
PubMed

Google Scholar
Hanlon KS, Kleinstiver BP, Garcia SP, Zaborowski MP, Volak A, Spirig SE, et al. High levels of AAV vector integration into CRISPR-induced DNA breaks. Nat Commun. 2019;10(1):4439.

Article
PubMed
PubMed Central

Google Scholar
Nelson CE, Wu Y, Gemberling MP, Oliver ML, Waller MA, Bohning JD, et al. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat Med. 2019;25(3):427–32.

Article
PubMed
PubMed Central
CAS

Google Scholar
Nerys-Junior A, Braga-Dias LP, Pezzuto P, Cotta-de-Almeida V, Tanuri A. Comparison of the editing patterns and editing efficiencies of TALEN and CRISPR-Cas9 when targeting the human CCR5 gene. Genet Mol Biol. 2018;19(41):167–79.

Article

Google Scholar
Miro F, Nobile C, Blanchard N, Lind M, Filipe-Santos O, Fieschi C, et al. T cell-dependent activation of dendritic cells requires IL-12 and IFN-γ signaling in T cells. J Immunol. 2006;177(6):3625–34.

Article
PubMed
CAS

Google Scholar
Gupta YH, Khanom A, Acton SE. Control of dendritic cell function within the tumor microenvironment. Front Immunol. 2022;13:733800.

Article
PubMed
PubMed Central
CAS

Google Scholar
Tenbusch M, Kuate S, Tippler B, Gerlach N, Schimmer S, Dittmer U, et al. Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity. BMC Immunol. 2008;9:1–5.

Article

Google Scholar
Stam AG, Santegoets SJ, Westers TM, Sombroek CC, Janssen JJ, Tillman BW, et al. CD40-targeted adenoviral GM-CSF gene transfer enhances and prolongs the maturation of human CML-derived dendritic cells upon cytokine deprivation. Br J Cancer. 2003;89(7):1162–5.

Article
PubMed
PubMed Central
CAS

Google Scholar
Ghasemi A, Martinez-Usatorre A, Li L, Hicham M, Guichard A, Marcone R, et al. Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy. Nature Cancer. 2024;5(2):240–61.

Article
PubMed
CAS

Google Scholar
Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res. 2015;21(10):2278–88.

Article
PubMed
PubMed Central
CAS

Google Scholar
Nguyen KG, Vrabel MR, Mantooth SM, Hopkins JJ, Wagner ES, Gabaldon TA, et al. Localized interleukin-12 for cancer immunotherapy. Front Immunol. 2020;11:575597.

Article
PubMed
PubMed Central
CAS

Google Scholar
Kim YS. Tumor therapy applying membrane-bound form of cytokines. Immune network. 2009;9(5):158.

Article
PubMed
PubMed Central

Google Scholar
Han J, Wang H. Cytokine-overexpressing dendritic cells for cancer immunotherapy. Exper Mole Med. 2024:1.
Stripecke R. Lentivirus-induced dendritic cells (iDC) for immune-regenerative therapies in cancer and stem cell transplantation. Biomedicines. 2014;2(3):229–46.

Article
PubMed
PubMed Central

Google Scholar
Gorodilova AV, Kitaeva KV, Filin IY, Mayasin YP, Kharisova CB, Issa SS, et al. The potential of dendritic cell subsets in the development of personalized immunotherapy for cancer treatment. Curr Issues Mol Biol. 2023;45(10):8053–70.

Article
PubMed
PubMed Central
CAS

Google Scholar
Panya A, Thepmalee C, Sawasdee N, Sujjitjoon J, Phanthaphol N, Junking M, et al. Cytotoxic activity of effector T cells against cholangiocarcinoma is enhanced by self-differentiated monocyte-derived dendritic cells. Cancer Immunol Immunother. 2018;67:1579–88.

Article
PubMed
PubMed Central
CAS

Google Scholar
Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20–37.

Article
PubMed
CAS

Google Scholar
Lu Q, Kou D, Lou S, Ashrafizadeh M, Aref AR, Canadas I, et al. Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy. J Hematol Oncol. 2024;17(1):16.

Article
PubMed
PubMed Central

Google Scholar
Wang B, Hu S, Teng Y, Chen J, Wang H, Xu Y, et al. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Signal Transduct Target Ther. 2024;9(1):200.

Article
PubMed
PubMed Central

Google Scholar
Hu X, Wu T, Bao Y, Zhang Z. Nanotechnology based therapeutic modality to boost antitumor immunity and collapse tumor defense. J Control Release. 2017;256:26–45.

Article
PubMed
CAS

Google Scholar
Tran TH, Tran TT, Nguyen HT, Dai Phung C, Jeong JH, Stenzel MH, et al. Nanoparticles for dendritic cell-based immunotherapy. Int J Pharm. 2018;542(1–2):253–65.

Article
PubMed
CAS

Google Scholar
Sui Y, Berzofsky JA. Trained immunity inducers in cancer immunotherapy. Front Immunol. 2024;15:1427443.

Article
PubMed
PubMed Central
CAS

Google Scholar
Yang D, Liu B, Sha H. Advances and prospects of cell-penetrating peptides in tumor immunotherapy. Sci Rep. 2025;15(1):3392.

Article
PubMed
PubMed Central
CAS

Google Scholar
Abd-Aziz N, Poh CL. Development of peptide-based vaccines for cancer. Journal of Oncology. 2022;2022(1):9749363.

PubMed
PubMed Central

Google Scholar
Srivastava P, Rütter M, Antoniraj G, Ventura Y, David A. dendritic cell-targeted nanoparticles enhance T cell activation and antitumor immune responses by boosting antigen presentation and blocking PD-L1 pathways. ACS Appl Mater Interfaces. 2024;16(40):53577–90.

Article
PubMed

Google Scholar
Cao Z, Yang X, Yang W, Chen F, Jiang W, Zhan S, et al. Modulation of dendritic cell function via nanoparticle-induced cytosolic calcium changes. ACS Nano. 2024;18(10):7618–32.

Article
PubMed
PubMed Central
CAS

Google Scholar
Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941–51.

Article
PubMed
PubMed Central
CAS

Google Scholar
Zelepukin IV, Shevchenko KG, Deyev SM. Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery. Nat Commun. 2024;15(1):4366.

Article
PubMed
PubMed Central
CAS

Google Scholar
Handa M, Beg S, Shukla R, Barkat MA, Choudhry H, Singh KK. Recent advances in lipid-engineered multifunctional nanophytomedicines for cancer targeting. J Control Release. 2021;340:48–59.

Article
PubMed
CAS

Google Scholar
Hajj KA, Whitehead KA. Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat Rev Mater. 2017;2:10 [Internet]. 2017 Sep 12 [cited 2025 Aug 25];2(10):1–17. Available from: https://www.nature.com/articles/natrevmats201756
Sabnis S, Kumarasinghe ES, Salerno T, Mihai C, Ketova T, Senn JJ, et al. A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates. Molecular Therapy [Internet]. 2018 Jun 6 [cited 2025 Aug 25];26(6):1509–19. Available from: https://www.sciencedirect.com/science/article/pii/S1525001618301187
Miao L, Lin J, Huang Y, Li L, Delcassian D, Ge Y, et al. Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver. Nature Commun. 2020;11:1 [Internet]. 2020 May 15 [cited 2025 Aug 25];11(1):1–13. Available from: https://www.nature.com/articles/s41467-020-16248-y
Kauffman KJ, Dorkin JR, Yang JH, Heartlein MW, Derosa F, Mir FF, et al. Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs. Nano Lett [Internet]. 2015 [cited 2025 Aug 25];15(11):7300–6. Available from: /doi/pdf/https://doi.org/10.1021/acs.nanolett.5b02497
Liu H, Moynihan KD, Zheng Y, Szeto GL, Li AV, Huang B, et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature. 2014;507(7493):519–22.

Article
PubMed
PubMed Central
CAS

Google Scholar
Gbian DL, Omri A. Lipid-based drug delivery systems for diseases managements. Biomedicines. 2022;10(9):2137.

Article
PubMed
PubMed Central
CAS

Google Scholar
Ndeupen S, Qin Z, Jacobsen S, Bouteau A, Estanbouli H, Igyártó BZ. The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. Iscience. 2021;24(12).
Alameh MG, Tombácz I, Bettini E, Lederer K, Ndeupen S, Sittplangkoon C, et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. 2021;54(12):2877–92.

Article
PubMed
PubMed Central
CAS

Google Scholar
Miao L, Li L, Huang Y, Delcassian D, Chahal J, Han J, et al. Delivery of mRNA vaccines with heterocyclic lipids increases antitumor efficacy by STING-mediated immune cell activation. Nat Biotechnol. 2019;37(10):1174–85.

Article
PubMed
CAS

Google Scholar
Connors J, Joyner D, Mege NJ, Cusimano GM, Bell MR, Marcy J, et al. Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals. Communications biology. 2023;6(1):188.

Article
PubMed
PubMed Central
CAS

Google Scholar
Zhang M, Wang Y, Li B, Yang B, Zhao M, Li B, Liu J, Hu Y, Wu Z, Ong Y, Han X. STING‐activating polymers boost lymphatic delivery of mRNA vaccine to potentiate cancer immunotherapy. Adv Mater. 2025:2412654.
Nguyen NT, Le XT, Lee WT, Lim YT, Oh KT, Lee ES, et al. STING-activating dendritic cell-targeted nanovaccines that evoke potent antigen cross-presentation for cancer immunotherapy. Bioactive Mater. 2024;42:345–65.

Article
CAS

Google Scholar
Chin EN, Yu C, Vartabedian VF, Jia Y, Kumar M, Gamo AM, et al. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. Science. 2020;369(6506):993–9.

Article
PubMed
CAS

Google Scholar
Wang Y, Li S, Hu M, Yang Y, McCabe E, Zhang L, et al. Universal STING mimic boosts antitumor immunity via preferential activation of tumor control signaling pathways. Nat Nanotechnol. 2024;19(6):856–66.

Article
PubMed
PubMed Central
CAS

Google Scholar
Nagy NA, De Haas AM, Geijtenbeek TB, Van Ree R, Tas SW, Van Kooyk Y, et al. Therapeutic liposomal vaccines for dendritic cell activation or tolerance. Front Immunol. 2021;12:674048.

Article
PubMed
PubMed Central
CAS

Google Scholar
Li S, Luo M, Wang Z, Feng Q, Wilhelm J, Wang X, et al. Prolonged activation of innate immune pathways by a polyvalent STING agonist. Nat Biomed Eng. 2021;5(5):455–66.

Article
PubMed
PubMed Central
CAS

Google Scholar
Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015;11(7):1018–30.

Article
PubMed
PubMed Central
CAS

Google Scholar
Hong C, Schubert M, Tijhuis AE, Requesens M, Roorda M, van den Brink A, et al. cGAS–STING drives the IL-6-dependent survival of chromosomally instable cancers. Nature. 2022;607(7918):366–73.

Article
PubMed
CAS

Google Scholar
Zhang C, Shang G, Gui X, Zhang X, Bai XC, Chen ZJ. Structural basis of STING binding with and phosphorylation by TBK1. Nature. 2019;567(7748):394–8.

Article
PubMed
PubMed Central
CAS

Google Scholar
He Y, Hong C, Yan EZ, Fletcher SJ, Zhu G, Yang M, Li Y, Sun X, Irvine DJ, Li J, Hammond PT. Self-assembled cGAMP-STINGΔTM signaling complex as a bioinspired platform for cGAMP delivery. Sci Adv. 2020;6(24):eaba7589.
Tse SW, McKinney K, Walker W, Nguyen M, Iacovelli J, Small C, et al. mRNA-encoded, constitutively active STINGV155M is a potent genetic adjuvant of antigen-specific CD8+ T cell response. Mol Ther. 2021;29(7):2227–38.

Article
PubMed
PubMed Central
CAS

Google Scholar
Shumilina E, Huber SM, Lang F. Ca2+ signaling in the regulation of dendritic cell functions. Am J Physiol Cell Physiol. 2011;300(6):C1205–14.

Article
PubMed
CAS

Google Scholar
Salter RD, Watkins SC. Dendritic cell altered states: what role for calcium? Immunol Rev. 2009;231(1):278–88.

Article
PubMed
CAS

Google Scholar
Santegoets SJ, van den Eertwegh AJ, van de Loosdrecht AA, Scheper RJ, de Gruijl TD. Human dendritic cell line models for DC differentiation and clinical DC vaccination studies. J Leucocyte Biol. 2008;84(6):1364–73.

Article
CAS

Google Scholar
Cabeza-Cabrerizo M, Cardoso A, Minutti CM, Pereira da Costa M, Reis e Sousa C. Dendritic cells revisited. Annu Rev Immunol. 2021;39(1):131–66.
Herbst C, Harshyne LA, Igyártó BZ. Intracellular monitoring by dendritic cells–a new way to stay informed–from a simple scavenger to an active gatherer. Front Immunol. 2022;13:1053582.

Article
PubMed
PubMed Central
CAS

Google Scholar
Sun X, Zhang Y, Li J, Park KS, Han K, Zhou X, et al. Amplifying STING activation by cyclic dinucleotide–manganese particles for local and systemic cancer metalloimmunotherapy. Nat Nanotechnol. 2021;16(11):1260–70.

Article
PubMed
PubMed Central
CAS

Google Scholar
Grippin A, Sayour E, Wummer B, Monsalve A, Wildes T, Dyson K, Mitchell DA. mRNA-nanoparticles to enhance and track dendritic cell migration. 2018;72.
Huang L, Liu Z, Wu C, Lin J, Liu N. Magnetic nanoparticles enhance the cellular immune response of dendritic cell tumor vaccines by realizing the cytoplasmic delivery of tumor antigens. Bioeng Transl Med. 2023;8(2):e10400.

Article
PubMed
CAS

Google Scholar
Lv M, Chen M, Zhang R, Zhang W, Wang C, Zhang Y, et al. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Res. 2020;30(11):966–79.

Article
PubMed
PubMed Central
CAS

Google Scholar
Wang S, Ni D, Yue H, Luo N, Xi X, Wang Y, et al. Exploration of antigen induced CaCO3 nanoparticles for therapeutic vaccine. Small. 2018;14(14):1704272.

Article

Google Scholar
Hu YX, Han XS, Jing Q. Ca (2+) ion and autophagy. Autophagy Biol Diseases Basic Sci. 2019;28:151–66.
Wang D, Rayani S, Marshall JL. Carcinoembryonic antigen as a vaccine target. Expert Rev Vaccines. 2008;7(7):987–93.

Article
PubMed
CAS

Google Scholar
Zhuang X, Wu T, Zhao Y, Hu X, Bao Y, Guo Y, et al. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2Kb and H-2Db-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma. J Control Release. 2016;228:26–37.

Article
PubMed
CAS

Google Scholar
Heng BC, Zhao X, Tan EC, Khamis N, Assodani A, Xiong S, et al. Evaluation of the cytotoxic and inflammatory potential of differentially shaped zinc oxide nanoparticles. Arch Toxicol. 2011;85:1517–28.

Article
PubMed
CAS

Google Scholar
Shi C, Jian C, Wang L, Gao C, Yang T, Fu Z, et al. Dendritic cell hybrid nanovaccine for mild heat inspired cancer immunotherapy. J Nanobiotechnol. 2023;21(1):347.

Article
CAS

Google Scholar
Lee SB, Ahn SB, Lee SW, Jeong SY, Ghilsuk Y, Ahn BC, Kim EM, Jeong HJ, Lee J, Lim DK, Jeon YH. Radionuclide-embedded gold nanoparticles for enhanced dendritic cell-based cancer immunotherapy, sensitive and quantitative tracking of dendritic cells with PET and Cerenkov luminescence. NPG Asia Mater. 2016;8(6):e281.
Lee IH, Kwon HK, An S, Kim D, Kim S, Yu MK, et al. Imageable antigen-presenting gold nanoparticle vaccines for effective cancer immunotherapy in vivo. Angewandte Chemie-International Edition. 2012;51(35):8800.

Article
PubMed
CAS

Google Scholar
Kang S, Ahn S, Lee J, Kim JY, Choi M, Gujrati V, et al. Effects of gold nanoparticle-based vaccine size on lymph node delivery and cytotoxic T-lymphocyte responses. J Control Release. 2017;256:56–67.

Article
PubMed
CAS

Google Scholar
Fernández TD, Pearson JR, Leal MP, Torres MJ, Blanca M, Mayorga C, et al. Intracellular accumulation and immunological properties of fluorescent gold nanoclusters in human dendritic cells. Biomaterials. 2015;43:1–2.

Article
PubMed

Google Scholar
Le Guével X, Perez Perrino M, Fernández TD, Palomares F, Torres MJ, Blanca M, et al. Multivalent glycosylation of fluorescent gold nanoclusters promotes increased human dendritic cell targeting via multiple endocytic pathways. ACS Appl Mater Interfaces. 2015;7(37):20945–56.

Article
PubMed

Google Scholar
Tomić S, Đokić J, Vasilijić S, Ogrinc N, Rudolf R, Pelicon P, et al. Size-dependent effects of gold nanoparticles uptake on maturation and antitumor functions of human dendritic cells in vitro. PLoS ONE. 2014;9(5):e96584.

Article
PubMed
PubMed Central

Google Scholar
Affandi AJ, Grabowska J, Olesek K, Lopez Venegas M, Barbaria A, Rodríguez E, et al. Selective tumor antigen vaccine delivery to human CD169+ antigen-presenting cells using ganglioside-liposomes. Proc Natl Acad Sci. 2020;117(44):27528–39.

Article
PubMed
PubMed Central
CAS

Google Scholar
Rosalia RA, Cruz LJ, van Duikeren S, Tromp AT, Silva AL, Jiskoot W, et al. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent antitumor responses. Biomaterials. 2015;40:88–97.

Article
PubMed
CAS

Google Scholar
Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res. 2011;17(8):2270–80.

Article
PubMed
CAS

Google Scholar
Rueda F, Eich C, Cordobilla B, Domingo P, Acosta G, Albericio F, et al. Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines. Immunobiology. 2017;222(11):989–97.

Article
PubMed
CAS

Google Scholar
Suzuki R, Utoguchi N, Kawamura K, Kadowaki N, Okada N, Takizawa T, Uchiyama T, Maruyama K. Development of effective antigen delivery carrier to dendritic cells via Fc receptor in cancer immunotherapy. Yakugaku Zasshi: J Pharmaceutical Soc Japan. 127(2):301–6.
Hossain MK, Vartak A, Sucheck S, Wall KA. Augmenting vaccine immunogenicity through the use of natural human anti-Rha antibodies and monoclonal Fc domains. J Immunol. 2018;200(1_Supplement):181–4.
Hossain MK, Vartak A, Sucheck SJ, Wall KA. Liposomal fc domain conjugated to a cancer vaccine enhances both humoral and cellular immunity. ACS Omega. 2019;4(3):5204–8.

Article
PubMed
PubMed Central
CAS

Google Scholar
Lahoud MH, Ahmet F, Zhang JG, Meuter S, Policheni AN, Kitsoulis S, et al. DEC-205 is a cell surface receptor for CpG oligonucleotides. Proc Natl Acad Sci. 2012;109(40):16270–5.

Article
PubMed
PubMed Central
CAS

Google Scholar
Saluja SS, Hanlon DJ, Sharp FA, Hong E, Khalil D, Robinson E, Tigelaar R, Fahmy TM, Edelson RL. Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen. Int J Nanomed. 2014:5231–46.
Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, Yamazaki S, et al. Differential antigen processing by dendritic cell subsets in vivo. Science. 2007;315(5808):107–11.

Article
PubMed
CAS

Google Scholar
Neubert K, Lehmann CH, Heger L, Baranska A, Staedtler AM, Buchholz VR, et al. Antigen delivery to CD11c+ CD8− dendritic cells induces protective immune responses against experimental melanoma in mice in vivo. J Immunol. 2014;192(12):5830–8.

Article
PubMed
CAS

Google Scholar
Luci C, Anjuère F. IFN-λs and BDCA3+/CD8α+ dendritic cells: towards the design of novel vaccine adjuvants? Expert Rev Vaccines. 2011;10(2):159–61.

Article
PubMed
CAS

Google Scholar
Tullett KM, Rojas IM, Minoda Y, Tan PS, Zhang JG, Smith C, et al. Targeting CLEC9A delivers antigen to human CD141+ DC for CD4+ and CD8+ T cell recognition. JCI insight. 2016;1(7):e87102.

Article
PubMed
PubMed Central

Google Scholar
Sehgal K, Ragheb R, Fahmy TM, Dhodapkar MV, Dhodapkar KM. Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15–dependent DC crosstalk. J Immunol. 2014;193(5):2297–305.

Article
PubMed
CAS

Google Scholar
Ghinnagow R, De Meester J, Cruz LJ, Aspord C, Corgnac S, Macho-Fernandez E, et al. Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses. Oncoimmunology. 2017;6(9):e1339855.

Article
PubMed
PubMed Central

Google Scholar
Schetters ST, Kruijssen LJ, Crommentuijn MH, Kalay H, Ochando J, Den Haan JM, et al. Mouse DC-SIGN/CD209a as target for antigen delivery and adaptive immunity. Front Immunol. 2018;9:990.

Article
PubMed
PubMed Central

Google Scholar
Stolk DA, De Haas A, Vree J, Duinkerken S, Lübbers J, Van de Ven R, et al. Lipo-based vaccines as an approach to target dendritic cells for induction of T-and iNKT cell responses. Front Immunol. 2020;11:990.

Article
PubMed
PubMed Central
CAS

Google Scholar
Gargett T, Abbas MN, Rolan P, Price JD, Gosling KM, Ferrante A, et al. Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma. Cancer Immunol Immunother. 2018;67:1461–72.

Article
PubMed
PubMed Central
CAS

Google Scholar
Kumar MA, Baba SK, Sadida HQ, Marzooqi SA, Jerobin J, Altemani FH, et al. Extracellular vesicles as tools and targets in therapy for diseases. Signal Transduct Target Ther. 2024;9(1):27.

Article
PubMed
PubMed Central

Google Scholar
Lorite P, Domínguez JN, Palomeque T, Torres MI. Extracellular vesicles: advanced tools for disease diagnosis, monitoring, and therapies. Int J Mol Sci. 2024;26(1):189.

Article
PubMed
PubMed Central

Google Scholar
Alexander M, Hu R, Runtsch MC, Kagele DA, Mosbruger TL, Tolmachova T, et al. Exosome-delivered microRNAs modulate the inflammatory response to endotoxin. Nat Commun. 2015;6(1):7321.

Article
PubMed
CAS

Google Scholar
Henao Agudelo JS, Braga TT, Amano MT, Cenedeze MA, Cavinato RA, Peixoto-Santos AR, et al. Mesenchymal stromal cell-derived microvesicles regulate an internal pro-inflammatory program in activated macrophages. Front Immunol. 2017;8:881.

Article
PubMed
PubMed Central

Google Scholar
Bian X, Xiao YT, Wu T, Yao M, Du L, Ren S, et al. Microvesicles and chemokines in tumor microenvironment: mediators of intercellular communications in tumor progression. Mol Cancer. 2019;18(1):50.

Article
PubMed
PubMed Central

Google Scholar
Patil SM, Sawant SS, Kunda NK. Exosomes as drug delivery systems: a brief overview and progress update. Eur J Pharm Biopharm. 2020;154:259–69.

Article
PubMed
CAS

Google Scholar
Johnson V, Vasu S, Kumar US, Kumar M. Surface-engineered extracellular vesicles in cancer immunotherapy. Cancers. 2023;15(10):2838.

Article
PubMed
PubMed Central
CAS

Google Scholar
Damo M, Wilson DS, Simeoni E, Hubbell JA. TLR-3 stimulation improves antitumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma. Sci Rep. 2015;5(1):17622.

Article
PubMed
PubMed Central
CAS

Google Scholar
Matsuzaka Y, Yashiro R. Regulation of extracellular vesicle-mediated immune responses against antigen-specific presentation. Vaccines. 2022;10(10):1691.

Article
PubMed
PubMed Central
CAS

Google Scholar
Horrevorts SK, Stolk DA, van de Ven R, Hulst M, van Het Hof B, Duinkerken S, et al. Glycan-modified apoptotic melanoma-derived extracellular vesicles as antigen source for antitumor vaccination. Cancers. 2019;11(9):1266.

Article
PubMed
PubMed Central
CAS

Google Scholar
Choi ES, Song J, Kang YY, Mok H. Mannose-modified serum exosomes for the elevated uptake to murine dendritic cells and lymphatic accumulation. Macromol Biosci. 2019;19(7):1900042.

Article

Google Scholar
Yang Q, Li S, Ou H, Zhang Y, Zhu G, Li S, et al. Exosome-based delivery strategies for tumor therapy: an update on modification, loading, and clinical application. J Nanobiotechnol. 2024;22(1):41.

Article

Google Scholar
Kalkusova K, Taborska P, Stakheev D, Smrz D. The role of miR-155 in antitumor immunity. Cancers. 2022;14(21):5414.

Article
PubMed
PubMed Central
CAS

Google Scholar
Asadirad A, Hashemi SM, Baghaei K, Ghanbarian H, Mortaz E, Zali MR, et al. Phenotypical and functional evaluation of dendritic cells after exosomal delivery of miRNA-155. Life Sci. 2019;219:152–62.

Article
PubMed
CAS

Google Scholar
Katti A, Diaz BJ, Caragine CM, Sanjana NE, Dow LE. CRISPR in cancer biology and therapy. Nat Rev Cancer. 2022;22(5):259–79.

Article
PubMed
CAS

Google Scholar
Jung IY, Lee J. Unleashing the therapeutic potential of CAR-T cell therapy using gene-editing technologies. Mol Cells. 2018;41(8):717–23.

PubMed
PubMed Central
CAS

Google Scholar
Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discovery. 2014;13(10):759–80.

Article
PubMed
CAS

Google Scholar
Gerlach AM, Steimle A, Krampen L, Wittmann A, Gronbach K, Geisel J, et al. Role of CD40 ligation in dendritic cell semimaturation. BMC Immunol. 2012;13:1–1.

Article

Google Scholar
Ferrer IR, Wagener ME, Song M, Kirk AD, Larsen CP, Ford ML. Antigen-specific induced Foxp3+ regulatory T cells are generated following CD40/CD154 blockade. Proc Natl Acad Sci. 2011;108(51):20701–6.

Article
PubMed
PubMed Central
CAS

Google Scholar
Liu J, Chang J, Jiang Y, Meng X, Sun T, Mao L, et al. Fast and efficient CRISPR/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger RNA nanoparticles. Adv Mater. 2019;31(33):1902575.

Article

Google Scholar
Oh SA, Wu DC, Cheung J, Navarro A, Xiong H, Cubas R, et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nature cancer. 2020;1(7):681–91.

Article
PubMed
CAS

Google Scholar
Wan T, Zhong J, Pan Q, Zhou T, Ping Y, Liu X. Exosome-mediated delivery of Cas9 ribonucleoprotein complexes for tissue-specific gene therapy of liver diseases. Sci Adv. 2022;8(37):eabp9435.
Usman WM, Pham TC, Kwok YY, Vu LT, Ma V, Peng B, et al. Efficient RNA drug delivery using red blood cell extracellular vesicles. Nat Commun. 2018;9(1):2359.

Article
PubMed
PubMed Central

Google Scholar
Gupta N, Polkoff K, Qiao L, Cheng K, Piedrahita J. 200 Developing exosomes as a mediator for CRISPR/Cas-9 delivery. Reprod Fertility Dev. 2019;31(1):225.
Abbasi R, Alamdari-Mahd G, Maleki-Kakelar H, Momen-Mesgin R, Ahmadi M, Sharafkhani M, Rezaie J. Recent advances in the application of engineered exosomes from mesenchymal stem cells for regenerative medicine. Euro J Pharmacol. 2025;177236.
Busatto S, Iannotta D, Walker SA, Di Marzio L, Wolfram J. A simple and quick method for loading proteins in extracellular vesicles. Pharmaceuticals. 2021;14(4):356.

Article
PubMed
PubMed Central
CAS

Google Scholar
Dubey S, Chen Z, Talis A, Molotkov A, Ali A, Mintz A, Momen-Heravi F. An exosome-based gene delivery platform for cell-specific CRISPR/Cas9 genome editing. bioRxiv. 2023;2023–06.
Bahadorani M, Nasiri M, Dellinger K, Aravamudhan S, Zadegan R. Engineering exosomes for therapeutic applications: decoding biogenesis, content modification, and cargo loading strategies. Int J Nanomed. 2024;7137–64.
Ye Y, Zhang X, Xie F, Xu B, Xie P, Yang T, et al. An engineered exosome for delivering sgRNA: Cas9 ribonucleoprotein complex and genome editing in recipient cells. Biomater Sci. 2020;8(10):2966–76.

Article
PubMed
CAS

Google Scholar
Whitley JA, Kim S, Lou L, Ye C, Alsaidan OA, Sulejmani E, et al. Encapsulating Cas9 into extracellular vesicles by protein myristoylation. J Extracellular Vesicles. 2022;11(4):e12196.

Article
CAS

Google Scholar
Osteikoetxea X, Silva A, Lázaro-Ibáñez E, Salmond N, Shatnyeva O, Stein J, et al. Engineered Cas9 extracellular vesicles as a novel gene editing tool. J Extracellular Vesicles. 2022;11(5):e12225.

Article
CAS

Google Scholar
Elsharkasy OM, Hegeman CV, Lansweers I, Cotugno OL, de Groot IY, de Wit ZE, Liang X, Garcia-Guerra A, Moorman NJ, Lefferts J, de Voogt WS. A modular strategy for extracellular vesicle-mediated CRISPR-Cas9 delivery through aptamer-based loading and UV-activated cargo release. BioRxiv. 2024;2024–05.
Yao X, Lyu P, Yoo K, Yadav MK, Singh R, Atala A, et al. Engineered extracellular vesicles as versatile ribonucleoprotein delivery vehicles for efficient and safe CRISPR genome editing. J Extracellular Vesicles. 2021;10(5):e12076.

Article
CAS

Google Scholar
Wang YL, Lee YH, Chou CL, Chang YS, Liu WC, Chiu HW. Oxidative stress and potential effects of metal nanoparticles: a review of biocompatibility and toxicity concerns. Environ Pollution [Internet]. 2024 Apr 1 [cited 2025 Aug 25];346:123617. Available from: https://www.sciencedirect.com/science/article/pii/S0269749124003312
Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Reviews Drug Discovery 2020 20:2 [Internet]. 2020 Dec 4 [cited 2025 Aug 25];20(2):101–24. Available from: https://www.nature.com/articles/s41573-020-0090-8
Pan Y, Zeng F, Luan X, He G, Qin S, Lu Q, et al. Polyamine-depleting hydrogen-bond organic frameworks unleash dendritic cell and T cell vigor for targeted CRISPR/Cas-assisted cancer immunotherapy. Adv Mater. 2025;37(13):2411886.

Article
CAS

Google Scholar
Lanza G, Gafà R, Maestri I, Santini A, Matteuzzi M, Cavazzini L. Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability. Mod Pathol. 2002;15(7):741–9.

Article
PubMed

Google Scholar
Wylie B, Macri C, Mintern JD, Waithman J. Dendritic cells and cancer: from biology to therapeutic intervention. Cancers. 2019;11(4):521.

Article
PubMed
PubMed Central
CAS

Google Scholar
Gardner A, Ruffell B. Dendritic cells and cancer immunity. Trends Immunol. 2016;37(12):855–65.

Article
PubMed
PubMed Central
CAS

Google Scholar
Rosa FF, Pires CF, Kurochkin I, Ferreira AG, Gomes AM, Palma LG, Shaiv K, Solanas L, Azenha C, Papatsenko D, Schulz O. Direct reprogramming of fibroblasts into antigen-presenting dendritic cells. Sci Immunol. 2018;3(30):eaau4292.
Rosa FF, Pires CF, Zimmermannova O, Pereira CF. Direct reprogramming of mouse embryonic fibroblasts to conventional type 1 dendritic cells by enforced expression of transcription factors. Bio-protocol. 2020;10(10):e3619.
Shimosakai R, Khalil IA, Kimura S, Harashima H. mRNA-Loaded lipid nanoparticles targeting immune cells in the spleen for use as cancer vaccines. Pharmaceuticals [Internet]. 2022 Aug 1 [cited 2025 Aug 25];15(8):1017. Available from: https://www.mdpi.com/1424-8247/15/8/1017/htm
Luozhong S, Yuan Z, Sarmiento T, Chen Y, Gu W, McCurdy C, et al. Phosphatidylserine lipid nanoparticles promote systemic RNA delivery to secondary lymphoid organs. Nano Lett [Internet]. 2022 Oct 26 [cited 2025 Aug 25];22(20):8304–11. Available from: /doi/pdf/https://doi.org/10.1021/acs.nanolett.2c03234
Verma A, Uzun O, Hu Y, Hu Y, Han HS, Watson N, et al. Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nat Mater. 2008;7(7):588–95.

Article
PubMed
PubMed Central
CAS

Google Scholar
Wang S, Zhu Y, Du S, Zheng Y. Preclinical Advances in LNP-CRISPR therapeutics for solid tumor treatment. Cells. 2024;13(7):568.

Article
PubMed
PubMed Central

Google Scholar
Chen G, Abdeen AA, Wang Y, Shahi PK, Robertson S, Xie R, et al. A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing. Nat Nanotechnol. 2019;14(10):974–80.

Article
PubMed
PubMed Central
CAS

Google Scholar
Wei T, Cheng Q, Min YL, Olson EN, Siegwart DJ. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat Commun. 2020;11(1):3232.

Article
PubMed
PubMed Central
CAS

Google Scholar
Zuris JA, Thompson DB, Shu Y, Guilinger JP, Bessen JL, Hu JH, et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol. 2015;33(1):73–80.

Article
PubMed
CAS

Google Scholar
Lin MJ, Svensson-Arvelund J, Lubitz GS, Marabelle A, Melero I, Brown BD, et al. Cancer vaccines: the next immunotherapy frontier. Nat Cancer. 2022;3(8):911–26.

Article
PubMed
CAS

Google Scholar
Lee YJ, Kim Y, Park SH, Jo JC. Plasmacytoid dendritic cell neoplasms. Blood Res. 2023;58(S1):S90–5.

Article
PubMed Central
CAS

Google Scholar
Jeng LB, Liao LY, Shih FY, Teng CF. Dendritic-cell-vaccine-based immunotherapy for hepatocellular carcinoma: clinical trials and recent preclinical studies. Cancers. 2022;14(18):4380.

Article
PubMed
PubMed Central
CAS

Google Scholar
Stevens D, Ingels J, Van Lint S, Vandekerckhove B, Vermaelen K. Dendritic cell-based immunotherapy in lung cancer. Front Immunol. 2021;12(11):620374.

Article

Google Scholar
Najafi S, Mortezaee K. Advances in dendritic cell vaccination therapy of cancer. Biomed Pharmacother. 2023;1(164):114954.

Article

Google Scholar
Pittet MJ, Di Pilato M, Garris C, Mempel TR. Dendritic cells as shepherds of T cell immunity in cancer. Immunity. 2023;56(10):2218–30.

Article
PubMed
PubMed Central
CAS

Google Scholar
Kumar C, Kohli S, Chiliveru S, Jain M, Sharan B. Complete remission of rare adenocarcinoma of the oropharynx with APCEDEN®(dendritic cell-based vaccine): a case report. Clinical Case Reports. 2017;5(10):1692.

Article
PubMed
PubMed Central

Google Scholar
Squadrito ML, Cianciaruso C, Hansen SK, De Palma M. EVIR: chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens. Nat Methods. 2018;15(3):183–6.

Article
PubMed
PubMed Central
CAS

Google Scholar
Hurvitz SA, Timmerman JM. Recombinant, tumor-derived idiotype vaccination for indolent B cell non-Hodgkin’s lymphomas: a focus on FavId™. Expert Opin Biol Ther. 2005;5(6):841–52.

Article
PubMed
CAS

Google Scholar
Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, Ravetch JV. Therapeutic activity of agonistic, human anti-CD40 monoclonal antibodies requires selective FcγR engagement. Cancer Cell. 2016;29(6):820–31.

Article
PubMed
PubMed Central
CAS

Google Scholar
Salomon R, Rotem H, Katzenelenbogen Y, Weiner A, Cohen Saban N, Feferman T, et al. Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting. Nat Cancer. 2022;3(3):287–302.

Article
PubMed
CAS

Google Scholar
Study Details. A study to investigate the novel agent BNT111 and cemiplimab in combination or as single agents in patients with advanced melanoma that has not responded to other forms of treatment. ClinicalTrials.gov [Internet]. [cited 2025 Aug 25]. Available from: https://clinicaltrials.gov/study/NCT04526899
Study Details. A study of the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC. ClinicalTrials.gov [Internet]. [cited 2025 Aug 25]. Available from: https://clinicaltrials.gov/study/NCT05968326
Study Details. A study of ELI-002 in subjects with KRAS mutated pancreatic ductal adenocarcinoma (PDAC) and other solid tumors. ClinicalTrials.gov [Internet]. [cited 2025 Aug 25]. Available from: https://clinicaltrials.gov/study/NCT04853017
Aznar MA, Planelles L, Perez-Olivares M, Molina C, Garasa S, Etxeberría I, et al. Immunotherapeutic effects of intratumoral nanoplexed poly I:C. J Immunother Cancer [Internet]. 2019 May 2 [cited 2025 Aug 25];7(1). Available from: https://jitc.bmj.com/content/7/1/116
Study Details. Study of TLR9 agonist vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab. ClinicalTrials.gov [Internet]. [cited 2025 Aug 25]. Available from: https://clinicaltrials.gov/study/NCT04401995
Cornel AM, Van Til NP, Boelens JJ, Nierkens S. Strategies to genetically modulate dendritic cells to potentiate antitumor responses in hematologic malignancies. Front Immunol. 2018;18(9):982.

Article

Google Scholar
Veron P, Allo V, Riviere C, Bernard J, Douar AM, Masurier C. Major subsets of human dendritic cells are efficiently transduced by self-complementary adeno-associated virus vectors 1 and 2. J Virol. 2007;81(10):5385–94.

Article
PubMed
PubMed Central
CAS

Google Scholar
Li Z, Wang X, Janssen JM, Liu J, Tasca F, Hoeben RC, Gonçalves MA. Precision genome editing using combinatorial viral vector delivery of CRISPR-Cas9 nucleases and donor DNA constructs. Nucleic Acids Res. 2025;53(2):gkae1213.
Zhang Y, Peng L, Mumper RJ, Huang L. Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. Biomaterials [Internet]. 2013 Nov 1 [cited 2025 Aug 25];34(33):8459–68. Available from: https://www.sciencedirect.com/science/article/pii/S014296121300848X
Tan PH, Beutelspacher SC, Xue SA, Wang YH, Mitchell P, McAlister JC, et al. Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood. 2005;105(10):3824–32.

Article
PubMed
CAS

Google Scholar
Khan SH. Genome-editing technologies: concept, pros, and cons of various genome-editing techniques and bioethical concerns for clinical application. Molecular Therapy Nucleic Acids. 2019;7(16):326–34.

Article

Google Scholar
Becker S, Boch J. TALE and TALEN genome editing technologies. Gene Genome Editing. 2021;1(2):100007.

Article

Google Scholar
Humbert JM, Halary F. Viral and non-viral methods to genetically modify dendritic cells. Curr Gene Ther. 2012;12(2):127–36.

Article
PubMed
CAS

Google Scholar
Asmamaw MM. Viral vectors for the in vivo delivery of CRISPR components: advances and challenges. Front Bioeng Biotechnol. 2022;12(10):895713.

Article

Google Scholar
Wei C, Liu J, Yu Z, Zhang B, Gao G, Jiao R. TALEN or Cas9–rapid, efficient and specific choices for genome modifications. J Genet Genomics. 2013;40(6):281–9.

Article
PubMed
CAS

Google Scholar
Boettcher M, McManus MT. Choosing the right tool for the job: RNAi, TALEN, or CRISPR. Mol Cell. 2015;58(4):575–85.

Article
PubMed
PubMed Central
CAS

Google Scholar
Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534:7607.

Article

Google Scholar
Zelkoski AE, Lu Z, Sukumar G, Dalgard C, Said H, Alameh MG, et al. Ionizable lipid nanoparticles of mRNA vaccines elicit NF-κB and IRF responses through toll-like receptor 4. NPJ Vaccines. 2025;10(1):1–13.

Article

Google Scholar
Kwon YJ, James E, Shastri N, Fréchet JMJ. In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. Proc Natl Acad Sci USA. 2005;102(51):18264–8.

Article
PubMed
PubMed Central
CAS

Google Scholar
Heidegger S, Gößl D, Schmidt A, Niedermayer S, Argyo C, Endres S, et al. Immune response to functionalized mesoporous silica nanoparticles for targeted drug delivery. Nanoscale. 2015;8(2):938–48.

Article

Google Scholar
Cha BG, Jeong JH, Kim J. Extra-large pore mesoporous silica nanoparticles enabling co-delivery of high amounts of protein antigen and toll-like receptor 9 agonist for enhanced cancer vaccine efficacy. ACS Cent Sci. 2018;4(4):484–92.

Article
PubMed
PubMed Central
CAS

Google Scholar
Hong X, Zhong X, Du G, Hou Y, Zhang Y, Zhang Z, et al. The pore size of mesoporous silica nanoparticles regulates their antigen delivery efficiency. Sci Adv. 2020;6(25):4462–81.

Article

Google Scholar
Wang X, Li X, Ito A, Sogo Y, Ohno T. Synergistic antitumor efficacy of a hollow mesoporous silica-based cancer vaccine and an immune checkpoint inhibitor at the local site. Acta Biomater. 2022;145:235–45.

Article
PubMed
CAS

Google Scholar
Huang Y, Nahar S, Alam MM, Hu S, McVicar DW, Yang D. Reactive oxygen species-sensitive biodegradable mesoporous silica nanoparticles harboring theravac elicit tumor-specific immunity for colon tumor treatment. ACS Nano. 2023;17(20):19740–52.

Article
PubMed
CAS

Google Scholar
Godakhindi V, Yazdimamaghani M, Dam SK, Ferdous F, Wang AZ, Tarannum M, et al. Optimized fabrication of dendritic mesoporous silica nanoparticles as efficient delivery system for cancer immunotherapy. Small. 2024;20(50):2402802.

Article
PubMed
PubMed Central
CAS

Google Scholar
Le Guével X, Palomares F, Torres MJ, Blanca M, Fernandez TD, Mayorga C. Nanoparticle size influences the proliferative responses of lymphocyte subpopulations. RSC Adv. 2015;5(104):85305–9.

Article

Google Scholar
Cho NH, Cheong TC, Min JH, Wu JH, Lee SJ, Kim D, et al. A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy. Nat Nanotechnol. 2011;6(10):675–82.

Article
PubMed
CAS

Google Scholar
Grippin AJ, Wummer B, Wildes T, Dyson K, Trivedi V, Yang C, et al. Dendritic cell-activating magnetic nanoparticles enable early prediction of antitumor response with magnetic resonance imaging. ACS Nano. 2019;13(12):13884–98.

Article
PubMed
PubMed Central
CAS

Google Scholar
Zhao N, Francis NL, Song S, Kholodovych V, Calvelli HR, Hoop CL, et al. CD36-Binding Amphiphilic Nanoparticles for Attenuation of α-Synuclein-Induced Microglial Activation. Adv Nanobiomed Res [Internet]. 2022 Jun 1 [cited 2025 Aug 25];2(6):2100120. Available from: https://doi.org/10.1002/anbr.202100120
Akita H, Kogure K, Moriguchi R, Nakamura Y, Higashi T, Nakamura T, et al. Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation. Journal of Controlled Release [Internet]. 2010 May 10 [cited 2025 Aug 25];143(3):311–7. Available from: https://www.sciencedirect.com/science/article/pii/S0168365910000210
Doedens AL, Stockmann C, Rubinstein MP, Liao D, Zhang N, DeNardo DG, et al. Macrophage expression of hypoxia-inducible factor-1α suppresses T-cell function and promotes tumor progression. Can Res. 2010;70(19):7465–75.

Article
CAS

Google Scholar
Chen WH, Lecaros RLG, Tseng YC, Huang L, Hsu YC. Nanoparticle delivery of HIF1α siRNA combined with photodynamic therapy as a potential treatment strategy for head-and-neck cancer. Cancer Lett [Internet]. 2015 Apr 1 [cited 2025 Aug 25];359(1):65–74. Available from: https://www.sciencedirect.com/science/article/pii/S0304383515000336?via%3Dihub
Wang M, Wang K, Liao X, Hu H, Chen L, Meng L, et al. Carnitine palmitoyltransferase system: a new target for anti-inflammatory and anticancer therapy? Front Pharmacol. 2021;26(12):760581.

Article

Google Scholar
Clark AT, Russo-Savage L, Ashton LA, Haghshenas N, Amselle NA, Schulman IG. A mutation in LXRα uncovers a role for cholesterol sensing in limiting metabolic dysfunction-associated steatohepatitis. Nature Communications 2025 16:1 [Internet]. 2025 Jan 28 [cited 2025 Aug 25];16(1):1–19. Available from: https://www.nature.com/articles/s41467-025-56565-8
Liu C, Wang J, Zhang Y, Zha W, Zhang H, Dong S, et al. Efficient delivery of PKN3 shRNA for the treatment of breast cancer via lipid nanoparticles. Bioorg Med Chem [Internet]. 2022 Sep 1 [cited 2025 Aug 25];69:116884. Available from: https://www.sciencedirect.com/science/article/pii/S0968089622002760
Sun C, Seranova E, Cohen MA, Chipara M, Roberts J, Astuti D, et al. NAD depletion mediates cytotoxicity in human neurons with autophagy deficiency. Cell Rep [Internet]. 2023 May 30 [cited 2025 Aug 25];42(5):112372. Available from: https://www.sciencedirect.com/science/article/pii/S2211124723003832
Grzywa TM, Sosnowska A, Matryba P, Rydzynska Z, Jasinski M, Nowis D, et al. Myeloid cell-derived arginase in cancer immune response. Front Immunol. 2020;15(11):938.

Article

Google Scholar
Truong B, Allegri G, Liu XB, Burke KE, Zhu X, Cederbaum SD, et al. Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency. Proc Natl Acad Sci U S A [Internet]. 2019 Oct 15 [cited 2025 Aug 25];116(42):21150–9. Available from: https://doi.org/10.1073/pnas.1906182116?download=true
Arjunan P, Kathirvelu D, Mahalingam G, Goel AK, Zacharaiah UG, Srivastava A, et al. Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders. Acta Pharm Sin B [Internet]. 2024 Jul 1 [cited 2025 Aug 25];14(7):2885–900. Available from: https://www.sciencedirect.com/science/article/pii/S2211383524001448
El Moukhtari SH, Garbayo E, Amundarain A, Pascual-Gil S, Carrasco-León A, Prosper F, et al. Lipid nanoparticles for siRNA delivery in cancer treatment. Journal of Controlled Release [Internet]. 2023 Sep 1 [cited 2025 Aug 25];361:130–46. Available from: https://www.sciencedirect.com/science/article/pii/S0168365923004789
Novitskiy S, Ryzhov S, Zaynagetdinov R, Goldstein A, Tikhomirov O, Biaggioni I, Carbone D, Feoktistov I, Dikov M. Adenosine and A2B adenosine receptor in regulation of dendritic cell differentiation and properties. Cancer Res. 2008;68(9_Supplement):2472.
Schiemann K, Belousova N, Matevossian A, Nallaparaju KC, Kradjian G, Pandya M, et al. Dual A2A/A2B Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth In Vivo. Mol Cancer Ther [Internet]. 2024 Nov 1 [cited 2025 Aug 25];23(11):1517–29. Available from: /mct/article/23/11/1517/749314/Dual-A2A-A2B-Adenosine-Receptor-Antagonist-M1069
Chen S, Li G, Jiang Z, Xu Y, Aipire A, Li J. Regulation of dendritic cell biology by amino acids and their transporters. Front Immunol. 2025;16:1626973.

Article
PubMed
PubMed Central

Google Scholar
Kim M, Tomek P. Tryptophan: a rheostat of cancer immune escape mediated by immunosuppressive enzymes IDO1 and TDO. Front Immunol. 2021;23(12):636081.

Article

Google Scholar
Endo R, Nakamura T, Kawakami K, Sato Y, Harashima H. The silencing of indoleamine 2,3-dioxygenase 1 (IDO1) in dendritic cells by siRNA-loaded lipid nanoparticles enhances cell-based cancer immunotherapy. Scientific Reports 2019 9:1 [Internet]. 2019 Aug 5 [cited 2025 Aug 25];9(1):1–11. Available from: https://www.nature.com/articles/s41598-019-47799-w
Singh M, Kapoor A, Bhatnagar A. Oxidative and reductive metabolism of lipid-peroxidation derived carbonyls. Chem Biol Interact. 2015;5(234):261–73.

Article

Google Scholar
Shan X, Zhao Z, Lai P, Liu Y, Li B, Ke Y, et al. RNA nanotherapeutics with fibrosis overexpression and retention for MASH treatment. Nature Communications 2024 15:1 [Internet]. 2024 Aug 27 [cited 2025 Aug 25];15(1):1–20. Available from: https://www.nature.com/articles/s41467-024-51571-8
Payen VL, Mina E, Van Hée VF, Porporato PE, Sonveaux P. Monocarboxylate transporters in cancer. Molecular Metabolism. 2020;1(33):48–66.

Article

Google Scholar
Elangovan S, Pathania R, Ramachandran S, Ananth S, Padia RN, Srinivas SR, et al. Molecular Mechanism of SLC5A8 Inactivation in Breast Cancer. Mol Cell Biol [Internet]. 2013 Oct 1 [cited 2025 Aug 25];33(19):3920. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3811868/
Pandey AR, Kumar A, Shrivastava NK, Singh J, Yadav S, Sonkar AB, et al. Advancing siRNA Therapeutics targeting MCT-4: A Multifaceted approach integrating Arithmetical Designing, Screening, and molecular dynamics validation. Int Immunopharmacol [Internet]. 2025 Feb 6 [cited 2025 Aug 25];147:113980. Available from: https://www.sciencedirect.com/science/article/pii/S1567576924025025
Setargew YF, Wyllie K, Grant RD, Chitty JL, Cox TR. Targeting lysyl oxidase family meditated matrix cross-linking as an anti-stromal therapy in solid tumors. Cancers. 2021;13(3):491.

Article
PubMed
PubMed Central
CAS

Google Scholar
Saatci O, Kaymak A, Raza U, Ersan PG, Akbulut O, Banister CE, et al. Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. Nature Communications 2020 11:1 [Internet]. 2020 May 15 [cited 2025 Aug 25];11(1):1–17. Available from: https://www.nature.com/articles/s41467-020-16199-4
Pappano WN, Zhang Q, Tucker LA, Tse C, Wang J. Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells. BMC Cancer [Internet]. 2014 Jun 13 [cited 2025 Aug 25];14(1):430. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4229861/
1Ray M, Lee YW, Hardie J, Mout R, Yeşilbag Tonga G, Farkas ME, et al. CRISPRed Macrophages for Cell-Based Cancer Immunotherapy. Bioconjug Chem [Internet]. 2018 Feb 21 [cited 2025 Aug 25];29(2):445–50. Available from: https://doi.org/10.1021/acs.bioconjchem.7b00768?ref=article_openPDF
Hamouda AEI, Filtjens J, Brabants E, Kancheva D, Debraekeleer A, Brughmans J, et al. Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic antitumor immunity. Nature Communications 2024 15:1 [Internet]. 2024 Dec 6 [cited 2025 Aug 25];15(1):1–20. Available from: https://www.nature.com/articles/s41467-024-54877-9
Richards DM, Sefrin JP, Gieffers C, Hill O, Merz C. Concepts for agonistic targeting of CD40 in immuno-oncology. Hum Vaccin Immunother. 2020;16(2):377–87.

Article
PubMed
CAS

Google Scholar
Zhu Y, Yao ZC, Li S, Ma J, Wei C, Yu D, et al. An mRNA lipid nanoparticle-incorporated nanofiber-hydrogel composite for cancer immunotherapy. Nature Communications 2025 16:1 [Internet]. 2025 Jul 1 [cited 2025 Aug 25];16(1):1–16. Available from: https://www.nature.com/articles/s41467-025-61299-8
Correa S, Meany EL, Gale EC, Klich JH, Saouaf OM, Mayer AT, et al. Injectable Nanoparticle‐Based Hydrogels Enable the Safe and Effective Deployment of Immunostimulatory CD40 Agonist Antibodies. Advanced Science [Internet]. 2022 Oct 1 [cited 2025 Aug 25];9(28):2103677. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9534946/
Xu Y, Xu X, Zhang Q, Lu P, Xiang C, Zhang L, et al. Gp130-dependent STAT3 activation in M-CSF–derived macrophages exaggerates tumor progression. Genes Diseases. 2024;11(3):100985.

Article
PubMed
CAS

Google Scholar
Zewdu A, Braggio D, Lopez G, Batte K, Khurshid S, Costas de Faria F, Bid HK, Koller D, Casadei L, Ladner KJ, Wang D. Blockade of interleukin-6 (IL-6) signaling in dedifferentiated liposarcoma (DDLPS) decreases mouse double minute 2 (MDM2) oncogenicity via alternative splicing. bioRxiv. 2024 Feb 22:2024–02.
Yang L, Yamagata N, Yadav R, Brandon S, Courtney RL, Morrow JD, et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Investig. 2003;111(5):727–35.

Article
PubMed
PubMed Central
CAS

Google Scholar
Wang Z, Chen Y, Wu H, Wang M, Mao L, Guo X, et al. Intravenous administration of IL-12 encoding self-replicating RNA-lipid nanoparticle complex leads to safe and effective antitumor responses. Sci Rep [Internet]. 2024 Dec 1 [cited 2025 Aug 25];14(1):1–15. Available from: https://www.nature.com/articles/s41598-024-57997-w
Hsu HH, Lin YM, Shen CY, Shibu MA, Li SY, Chang SH, et al. Prostaglandin E2-Induced COX-2 Expressions via EP2 and EP4 Signaling Pathways in Human LoVo Colon Cancer Cells. Int J Mol Sci [Internet]. 2017 Jun 1 [cited 2025 Aug 25];18(6):1132. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5485956/
Ahn YH, Hong SO, Kim JH, Noh KH, Song KH, Lee YH, et al. The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumor antigen-specific CD8+ T cell immunity. Clin Exp Immunol [Internet]. 2015 Jul 1 [cited 2025 Aug 25];181(1):164. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4469167/
Li X, Jiang W, Dong S, Li W, Zhu W, Zhou W. STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer. Biomolecules 2022, Vol 12, Page 1450 [Internet]. 2022 Oct 9 [cited 2025 Aug 25];12(10):1450. Available from: https://www.mdpi.com/2218-273X/12/10/1450/htm
Yokosawa T, Wakasugi K. Tryptophan-starved human cells overexpressing tryptophanyl-tRNA synthetase enhance high-affinity tryptophan uptake via enzymatic production of tryptophanyl-AMP. Int J Mol Sci. 2023;24(20):15453.

Article
PubMed
PubMed Central
CAS

Google Scholar
Wight TN, Kang I, Evanko SP, Harten IA, Chang MY, Pearce OM, et al. Versican—a critical extracellular matrix regulator of immunity and inflammation. Front Immunol. 2020;24(11):512.

Article

Google Scholar
Johnson LA, Banerji S, Lagerholm BC, Jackson DG. Dendritic cell entry to lymphatic capillaries is orchestrated by CD44 and the hyaluronan glycocalyx. Life Sci Alliance. 2021;4(5).
Chen H, Bian A, Zhou W, Miao Y, Ye J, Li J, et al. Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment. ACS Cent Sci [Internet]. 2024 Mar 27 [cited 2025 Aug 25];10(3):579–94. Available from: https://doi.org/10.1021/acscentsci.3c01440
Avilla E, Guarino V, Visciano C, Liotti F, Svelto M, Krishnamoorthy GP, et al. Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer. Cancer Res [Internet]. 2011 Mar 1 [cited 2025 Aug 25];71(5):1792–804. Available from: /cancerres/article/71/5/1792/575377/Activation-of-TYRO3-AXL-Tyrosine-Kinase-Receptors
Huelse JM, Bhasin SS, Jacobsen KM, Yim J, Thomas BE, Branella GM, et al. MERTK inhibition selectively activates a DC–T-cell axis to provide anti-leukemia immunity. Leukemia. 2024;38(12):2685–98.

Article
PubMed
CAS

Google Scholar
Im K, Choi YJ, Kim DH, Kim DS, Ban K, Ji W, et al. AXL receptor tyrosine kinase inhibition improves the antitumor effects of CD8+ T cells by inducing CD103+ dendritic cell-mediated T cell priming. Biochem Biophys Res Commun. 2023;5(680):7–14.

Article

Google Scholar
Sather S, Kenyon KD, Lefkowitz JB, Liang X, Varnum BC, Henson PM, et al. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood [Internet]. 2007 Feb 1 [cited 2025 Aug 25];109(3):1026–33. Available from: https://doi.org/10.1182/blood-2006-05-021634
Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol [Internet]. 2011 Nov 30 [cited 2025 Aug 25];29(11):1046–51. Available from: https://www.nature.com/articles/nbt.1990
Schroeder GM, An Y, Cai ZW, Chen XT, Clark C, Cornelius LAM, et al. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4- ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the met kinase superfamily. J Med Chem [Internet]. 2009 Mar 12 [cited 2025 Aug 25];52(5):1251–4. Available from: https://doi.org/10.1021/jm801586s
Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia [Internet]. 2009 Nov 27 [cited 2025 Aug 25];23(3):477–85. Available from: https://www.nature.com/articles/leu2008334
Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD, et al. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci. 2015;112(21):6682–7.

Article
PubMed
PubMed Central
CAS

Google Scholar
Moon TJ, Ta HM, Bhalotia A, Paulsen KE, Hutchinson DW, Arkema GM, et al. Nanoparticles targeting immune checkpoint protein VISTA induce potent antitumor immunity. J Immunother Cancer [Internet]. 2024 Aug 28 [cited 2025 Aug 25];12(8):8977. Available from: https://jitc.bmj.com/content/12/8/e008977
Zhang Y, Wu L, Li Z, Zhang W, Luo F, Chu Y, et al. Glycocalyx-Mimicking Nanoparticles Improve Anti-PD-L1 Cancer immunotherapy through reversion of tumor-associated macrophages. Biomacromolecules [Internet]. 2018 Jun 11 [cited 2025 Aug 25];19(6):2098–108. Available from: https://doi.org/10.1021/acs.biomac.8b00305
Kartikasari AE, Prakash MD, Cox M, Wilson K, Boer JC, Cauchi JA, et al. Therapeutic cancer vaccines—T cell responses and epigenetic modulation. Front Immunol. 2019;25(9):3109.

Article

Google Scholar
Yang W, Zhu G, Wang S, Yu G, Yang Z, Lin L, et al. In situ dendritic cell vaccine for effective cancer immunotherapy. ACS Nano. 2019;13(3):3083–94.

Article
PubMed
CAS

Google Scholar
Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol. 2013;24(7):1813–21.

Article
PubMed
PubMed Central
CAS

Google Scholar
Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy—current perspectives and future directions. Cell. 2023;186(8):1652–69.

Article
PubMed
CAS

Google Scholar
Dai JM, Zhang XQ, Zhang JJ, Yang WJ, Yang XM, Bian H, et al. Blockade of mIL-6R alleviated lipopolysaccharide-induced systemic inflammatory response syndrome by suppressing NF-κB-mediated Ccl2 expression and inflammasome activation. MedComm (Beijing) [Internet]. 2022 Jun 1 [cited 2025 Aug 25];3(2):e132. Available from: https://doi.org/10.1002/mco2.132
Sato K. Suppression of gp130 attenuated insulin-mediated signaling and glucose uptake in skeletal muscle cells. Sci Rep [Internet]. 2024 Dec 1 [cited 2025 Aug 25];14(1):1–9. Available from: https://www.nature.com/articles/s41598-024-68613-2

Category: 3. Business

Knee-jerk corporate responses to data leaks protect brands like Qantas — but consumers are getting screwed | Cybercrime

Continue Reading

Geoffrey Hinton says tech giants can’t profit from AI investments unless human labor is replaced

Continue Reading

Adaptive ER stress promotes mitochondrial remodelling and longevity through PERK-dependent MERCS assembly

PERK promotes myogenesis in myoblasts subjected to physiological levels of ER stressors

PERK promotes MERCS assembly and mitochondrial adaptations during adaptive UPR

PERK is required for adaptive UPR^ER activation of autophagy and mitophagy

Early-life induction of the UPR^ER extends lifespan and preserves healthspan in C. elegans

Early-life induction of the UPR promotes lifespan extension in C. elegans through modulation of lipid metabolism and lysosome activation

Early-life UPR induction stimulates MERCS formation, mitochondrial capacity and mitophagy in C. elegans

PEK-1 (UPR^ER) and ATFS-1 (UPR^mt) crosstalk regulates the adaptations promoted by the UPR in C. elegans

Continue Reading

Losses Worsening 49.3% Per Year, Revenue Forecast to Trail Market Heading Into Earnings

Continue Reading

Evaluating Valuation After Q3 Earnings Beat, Dividend Hold, and Canadian Acquisition

Continue Reading

CommScope (COMM) Returns to Profitability, but One-Off Loss Highlights Risks to Bullish Narratives

Continue Reading

From fast food to beverage giants, brands see rising income inequality among customers

The widening K

Two kinds of consumers

Washington is watching

The wealthy keep shopping

Beyond consumer spending

Continue Reading

MicroStrategy Falls Short Of Investment Grade In First S&P Global Credit Ranking

Continue Reading

Conversion of ADRs into Ordinary Shares listed on the NYSE

Continue Reading

Innovative gene engineering and drug delivery systems for dendritic cells in cancer immunotherapy | Journal of Biomedical Science

Continue Reading

Category: 3. Business

PERK promotes myogenesis in myoblasts subjected to physiological levels of ER stressors

PERK promotes MERCS assembly and mitochondrial adaptations during adaptive UPR

PERK is required for adaptive UPRER activation of autophagy and mitophagy

Early-life induction of the UPRER extends lifespan and preserves healthspan in C. elegans

Early-life induction of the UPR promotes lifespan extension in C. elegans through modulation of lipid metabolism and lysosome activation

Early-life UPR induction stimulates MERCS formation, mitochondrial capacity and mitophagy in C. elegans

PEK-1 (UPRER) and ATFS-1 (UPRmt) crosstalk regulates the adaptations promoted by the UPR in C. elegans

The widening K

Two kinds of consumers

Washington is watching

The wealthy keep shopping

Beyond consumer spending

PERK is required for adaptive UPR^ER activation of autophagy and mitophagy

Early-life induction of the UPR^ER extends lifespan and preserves healthspan in C. elegans

PEK-1 (UPR^ER) and ATFS-1 (UPR^mt) crosstalk regulates the adaptations promoted by the UPR in C. elegans